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Abstract  
Chronic kidney disease (CKD) affects almost 10% of the adult population worldwide. 
Regardless of the initial cause of renal injury, renal fibrosis is the final common pathway of all 
forms of CKD, including diabetic kidney disease (DKD). However, current therapies to 
attenuate the development of progressive renal fibrosis are limited to blockade of the renin-
angiotensin-aldosterone system (RAAS), achievement of blood pressure targets and in the 
case of DKD, blood glucose control. More recently inhibition of sodium-glucose linked 
transporter-2 has shown impressive renoprotective benefits in secondary analyses of major 
cardiovascular end-point trials. However, studies, where renal disease is a primary endpoint, 
are awaited. Given the personal and societal impacts of the increasing burden of CKD, it is of 
utmost importance to identify novel interventions for preventing the progressive renal 
fibrosis and thus progressive CKD. 
Receptor-interacting serine/threonine-protein kinase (RIPK) 3, known as a necroptotic 
kinase, is recognised to be involved in various innate immune responses, including 
necroptosis and activation of the toll-like receptor (TLR) 2 and 4 pathways and the pyrin 
domain-containing protein (NLRP) 3 inflammasome. However, the role of RIPK3 in the 
development of renal cortical fibrosis, and in particular in the pathology observed in the 
renal tubule under conditions that stimulate a fibrotic response has not been elucidated. 
In this thesis, mouse models of folic acid (FA)-induced nephropathy (studied at 28 days) and 
streptozotocin (STZ)-induced diabetic nephropathy (studied at 24 weeks) were developed. 
RIPK3 knock out (KO) mice were used to determine the therapeutic effect of RIPK3 in renal 
fibrosis, and the RIPK3 inhibitor dabrafenib was utilized as a pharmacological inhibitor of 
RIPK3. Human proximal tubular cells exposed to transforming growth factor beta-β1 (TGF-
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β1) were used as in vitro model to determine the role of necroptosis in the development of 
tubular pathology under pro-fibrotic influences. Inflammatory and fibrotic markers, as well 
as the relevant signalling pathways, were examined.  
Our results show that blockade of RIPK3 genetically or pharmacologically suppressed FA-
induced activation of the TLR2 and 4 pathways, the NLRP3 inflammasome and TGF-β1 
expression, associated with a reduced myofibroblast activation and interstitial extracellular 
matrix (ECM) deposition. RIPK3 inhibition also confers renoprotection in the STZ-induced 
diabetic nephropathy model. A reduction of TGF-β1, NLRP3 activation and TLR4 but not 
TLR2 was observed in RIPK3 KO mice. Inhibition of necroptosis also reduced TGF-β1 and 
ECM secretion in tubular cells exposed to TGF-β1. Collectively, the data shown in the thesis 
uniquely demonstrate that RIPK3 is involved in the development of renal fibrosis via 
multiple pathways, including necroptosis, TLR2 and 4 signalling and activation of the NLRP3 
inflammasome. Given the two strategies to inhibit RIPK3 converge on inhibition of the TLR4 
pathway and the NLRP3 inflammasome activation, we consider these are key pathways to 
inhibit to confer renoprotection. Dabrafenib, the RIPK3 inhibitor, deserves further 
exploration for repurposing as a targeted renal therapy. 
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Chapter 1 Introduction 
Chronic kidney disease (CKD) is defined as the presence of abnormal kidney function, 
including a loss of glomerular filtration and or proteinuria, persisting for at least 3 months. In 
the majority of cases CKD eventually leads to end-stage kidney disease (ESKD) requiring renal 
replacement therapy or death will ensue. CKD affects a large proportion of the population 
and considerably more than is widely appreciated by the general public. In 2014-5 1.7 million 
hospitalisations were associated with CKD, which accounts for 17% of all hospitalisations in 
Australia. Of those hospitalisations, 80% were for regular dialysis [1]. Having CKD increases 
the length of stay, cost and complications of non-CKD related hospital admissions.  In US, the 
overall prevalence of CKD in the adult general population was 14.8% in 2011-2014 [2]. 
Regardless of the cause of the initial renal injury, progressive renal fibrosis is common to all 
forms of CKD, characterized pathologically by extracellular matrix (ECM) accumulation, 
myofibroblast activation and inflammatory cell infiltration [3, 4].  
 
To date, inhibition of the renin-angiotensin-aldosterone system (RAAS) is the key strategy 
utilised to slow deterioration of renal functional decline [5]. However, this influences 
intrarenal and extrarenal haemodynamics and only secondarily reduces the development of 
renal fibrosis [5, 6].  It is primarily beneficial in those with proteinuric renal disease and at 
best it delays the time to ESKD, leading to renal replacement therapy or death, by a factor of 
months. Thus, novel therapies directed to reducing the fibrotic response in the kidney is 
urgently needed to arrest the progression of CKD and improve the outcome of patients. 
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It is known that inflammatory pathways play a central role in the progression of renal 
fibrosis [7]. Inflammation is incited by local and systemic factors and may be differentially 
activated in different forms of kidney disease. However, it is now well recognised that renal 
diseases traditionally considered as ‘non-inflammatory’, such as diabetic nephropathy, have 
a significant component of inflammation underpinning progressive disease. They include 
tubular-derived proinflammatory cytokines (such as, but not limited to, transforming growth 
factor beta-β1 (TGF-β1), macrophage chemotactic protein-1 (MCP-1), tumour necrosis 
factor (TNF)-α, interleukin (IL)-1β) [8, 9], tubular injury associated pathways (such as Wnt/β-
catenin signalling, Notch signalling) [10] and immune cells in promoting kidney injury and 
repair (such as  macrophages, T- and B-cells) [11]. Recently, a broader recognition of 
inflammatory responses contributing to fibrogenesis has been recognised to be due to 
activation of the innate immune response. These responses are initiated by several classes 
of pattern recognition receptors (PRRs) in response to immune activators such as pathogen-
associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) 
[12]. To date, the most recognised innate immune responses contributing to renal fibrosis 
are toll-like receptor (TLR)s pathways and the pyrin domain-containing protein 3 (NLRP3) 
inflammasome [13]. 
 
Necroptosis is a programmed cell necrosis process initiated by receptor-interacting protein 
kinase-3/1 (RIPK3/1) phosphorylation of mixed-lineage kinase domain-like protein (MLKL), 
resulting in necroptosis associated DAMP production, inflammation and tissue damage [14, 
15]. Recent studies have reported that blockade of necroptosis with the inhibitor Nec-1 
reduces the interstitial fibrotic response in the kidney in both the unilateral ureteral 
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obstruction (UUO) mouse model [16] and in rats subjected to subtotal nephrectomy (SNx) 
[17]. Although the mechanism remains unclear, these studies highly suggest that activation 
of the necroptotic pathway as a consequence of renal injury contributes to renal fibrosis. 
 
 It is increasingly reported that blocking of RIPK3, RIPK1 or MLKL reduces necroptotic cell 
death [18-20]. However, RIPK1 has been paradoxically demonstrated to protect hepatocytes 
from death in the Fas-induced hepatitis model [21], suggesting that RIPK1 might serve 
multiple roles resulting in both mediating and conversely protecting cells from death, which 
is likely to be context specific. In addition, it has reported deficiency of MLKL failed to 
protect the kidney from fibrosis [22]. Hence targeting either RIPK1 or MLKL may not be an 
effective strategy to inhibit renal fibrosis. Given the inhibitor of RIPK3, dabrafenib is already 
used clinically in patients with non-small cell lung cancer and melanoma, if proven 
efficacious, the route to market in patients with CKD would be accelerated. Consequently, 
my thesis has focused on the effectiveness of inhibiting RIKP3 to reduce renal disease in two 
models of CKD. To support the mechanism, I also undertook in vitro studies to explore the 
role of necroptosis in the fibrotic response. 
 
As discussed above, DAMPs are important triggers that activate the innate immune 
response. Recent studies in a macrophage cell culture model confirmed that activation of 
the NLRP3 inflammasome can be mediated by all three necroptotic kinases, i.e RIPK1, RIPK3 
and MLKL acting in a coordinated manner [23-27]. However, of note, RIPK3 can directly 
promote NLRP3 inflammasome activation, independent of its kinase activity and without 
concomitant necroptosis. RIPK3 has been demonstrated to promote cell-death-independent 
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inflammation through toll-like receptor (TLR) 4 activation in macrophages [28]. These 
studies implicate RIPK3 in the innate immune response via multiple mechanisms including 
necroptosis, as well as activation of the NLRP3 inflammasome and the TLR4 pathway. Hence 
targeting RIPK3 may limit several mechanisms that collectively contribute to renal fibrosis. A 
very recent report has also demonstrated that RIPK3 promotes renal fibrosis via the AKT-
dependent ATP citrate lyase (ACL), improving the survival and proliferation of fibroblasts in 
both the UUO-induced and adenine diet-induced renal fibrosis models [22]. However, the 
role of RIPK3 in a model of acute tubular necrosis leading to renal cortical fibrosis and in 
diabetic nephropathy has not been elucidated. Thus, the central hypothesis of this thesis is 
that blockade of RIPK3 will mitigate or limit the development of renal fibrosis. 
 
The first chapter of my thesis serves as the introduction (Chapter 1), which describes the 
research problem explored in this thesis and addresses the overall objectives and specific 
aims of the thesis. Chapter 2, the literature review, provides a summary of the current 
literature, which provides a basic understanding of the research presented in this study. 
Firstly, renal physiology and typical fibrotic processes in the kidney are described. Cellular 
and molecular pathways of renal fibrosis, the mechanisms driving the fibrotic processes and 
current research in development aimed at the treatment of renal fibrosis are then outlined. 
Emphasis is placed on the TGF-β signalling pathway due to its central role in fibrotic and 
innate immune responses. Then, common animal models of renal fibrosis are discussed, 
with a focus on the models presented in this study. Lastly, RIPK3 is introduced, its function, 
its role in necroptosis, inflammation, and our hypothesis of the renoprotective effects in 
kidney disease and current RIPK3 pharmacological blockers. 
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The studies presented in this thesis were determined to examine the therapeutic potential 
of RIPK3 inhibition in renal fibrosis. The experimental protocols utilised in my studies are 
detailed in Chapter 3.  Experimental details of procedures specific to certain studies are 
included within the respective chapters.  
 
The subsequent chapters describe the experimental outcomes of my investigations into the 
pathological role of RIPK3 in the development of renal fibrosis and the efficacy of various 
strategies to block RIPK3.  To address the aim of my thesis, mouse models of folic acid (FA)-
induced nephropathy (studied at 28 days) and streptozotocin (STZ)-induced diabetic 
nephropathy (studied at 24 weeks) were developed (Chapter 4 and 5). My data shows that 
FA nephropathy induces a significant upregulation of RIPK3 expression within the kidney. FA 
nephropathy developed in the RIPK3-/- mouse model or using the RIPK3 inhibitor 
dabrafenib attenuated the FA-induced fibrotic response, resulted in reduced renal 
interstitial collagen deposition. A consistent decrease of TLR2 and 4 activation, NLRP3 
activation and TGF-β1 expression were observed using both strategies to inhibit RIPK3. 
However, the activity of necroptosis was differentially affected in the knock out model and 
by the inhibitor dabrafenib. These results suggest that the activation of TLR2 and 4 signalling 
and NLRP3 activation is central to the fibrogenesis observed in FA-induced nephropathy 
(Chapter 4).  
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To confirm our findings of RIPK3 on NLRP3 and TLRs, we determined the effect of blockade 
of RIPK3 in two STZ animal models of diabetic nephropathy namely RIPK3-/- and 
endothelium-derived nitric oxide synthase (eNOS) -/- treated with dabrafenib. Consistently, 
RIPK3 inhibition with either gene knock out or the inhibitor reduced the fibrotic response 
and conferred renoprotection. A reduction of TGF-β1, NLRP3 activation and TLR4 but not 
TLR2 was seen (Chapter 5). Therefore, we conclude that RIPK3 mediates renal fibrosis 
mainly via activation of the NLRP3 inflammasome and the TLR4 pathway.  
 
Although we confirmed that the role of RIPK3 in fibrosis can be independent of necroptosis, 
a role for necroptosis in renal fibrosis cannot be excluded. Nec-1s inhibits necroptosis via 
inhibiting RIPK1 thereby the formation of the RIPK1-RIPK3 necrosome which induces 
downstream necroptosis [29]. I assessed the fibrotic response in human proximal tubular 
cells (PTCs) exposed to TGF-β1 exposed to the necroptotic inhibitor Nec-1s. Hence this 
strategy selectively inhibited necroptosis but did not limit the effect of RIPK3 on other 
pathways such as activation of TLR4 or NLRP3 inflammasome. Our data suggest that Nec-1s 
reduced TGF-β1 induced ECM secretion and TGF-β expression (Chapter 6), suggesting that 
necroptosis may also contribute to renal fibrosis. However, our in vivo models suggest that 
necroptosis is unlikely to be the major pathways contributing to the renal injury. 
 
Collectively, our findings confirm: 
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1: RIPK3 is a crucial mediator in renal fibrosis. Blockade of RIPK3 attenuates renal fibrosis 
with an accompanying reduction in both innate and adaptive inflammatory responses, 
myofibroblast activation and ECM deposition.  
2: The renoprotective effects of RIPK3 is primarily due to inhibition of the TLR4 pathway and 
NLRP3 inflammasome activation. However, a reduction in necroptosis, TGF-β1 activation 
and inhibition of downstream signalling may also contribute to a reduction in renal fibrosis. 
3: The pharmacological inhibitor of RIPK3, dabrafenib, afforded renoprotection and may be 
considered for repurposing as a targeted renal therapy in patients with CKD.  
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Chapter 2 Literature review 
2.1 Origin of renal fibrosis 
2.1.1 Renal physiology 
Kidneys are essential organs that maintain fluid, electrolyte and acid /base homeostasis as 
well as regulating blood pressure, vitamin D homeostasis and erythropoesis. The essential 
structural and functional unit of the kidney is known as nephron, consisting of a renal 
corpuscle including the glomerular tuft and a tubule unit (Figure 2.1). In the physiological 
context, a nephron serves as a functional unit to filter blood, reabsorb the filtered 
electrolytes, solutes and fluid, and excrete wastes and excessive electrolytes and water. In 
this process, the glomerulus is responsible for filtering blood, whilst tubules are responsible 
for reabsorbing 99% of the filtered electrolytes and water and returning them to the 
circulation [30, 31].  
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Figure 2.1 Schematic depiction of the nephron. Water and small molecular solute pass from 
the glomerular capillaries into the urinary space, whereas protein and red blood cells are 
normally restricted from passing through the glomerular filter due to size or charge sensitive 
exclusion. Ninety-nine percent of the filtrate is reabsorbed in the renal tubule [32]. 
 
2.1.2 CKD  
CKD is characterized by the loss of renal cells and their replacement by ECM, known as the 
pathogenesis of fibrosis, leading to the renal dysfunction [33]. CKD is defined as an 
estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2 or a urine albumin-
to-creatinine ratio (ACR) more than 3mg/mmol persisting for more than 3 months. The 
Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline divides CKD 
stages by proposing six categories of kidney function (eGFR) and three categories of 
albuminuria (ACR, A1–A3) (table 2.1). In the late-stage of CKD (G 4 and 5), some diseases 
specific therapies are available. However, when interstitial fibrosis and tubular atrophy 
occur generic supportive therapies directed to blood pressure control, reduction in 
albuminuria and reducing cardiovascular risk are the mainstays of therapy. 
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Table 2.1  GFR and Albuminuria categories in CKD [34]. *Relative to young adult level. 
**Including nephrotic syndrome. 
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate; AER, albumin 
excretion rate; ACR, albumin-to-creatinine ratio. 
 
According to the 2013 global burden of disease study, CKD increased from 28th in 1990 to 
20th in 2013 in the global ranking of the number of death and disability-adjusted life years 
[35]. In Central Latin America this change moved from 18th in 1990 to 7th in 2013, whilst it 
changed from 15th in 1990 to 12th in 2013 for Western Europe [36]. To date, in all 
developed and many developing countries, diabetes and hypertension are the leading 
causes of CKD, while glomerulonephritis and unknown causes are more common in Asian 
and sub-Saharan African countries. This difference may due to the decreased burden of 
chronic infectious diseases and environmentally induced nephrotoxins in developed 
countries [37]. Infectious diseases remain prevalent in low-income countries, which are 
associated with poor sanitation, high water fluorides, and high concentrations of disease-
transmitting vectors [38]. In addition, the burden of CKD in developing countries correlates 
with environmental pollution, pesticides, analgesic abuse, herbal medications, and the use 
of unregulated food additives [39, 40]. 
 
Fibrosis of the kidney is the end result of all forms of progressive kidney disease, leading to 
an inexorable loss of renal function and eventually death or renal replacement therapy. The 
kidney is a complex organ with highly specialized structures which can differentially undergo 
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fibrosis depending on the underlying disease. For example, the main function of glomerulus 
is filtration. Trapped immune complexes in the glomerular basement membrane (GBM) or in 
situ from circulating and then filtered antibodies and glomerular antigens can result in a 
cascade of inflammation and development of glomerulonephritis. Chronic 
glomerulonephritis may then stimulate scar formation, leading to glomerulosclerosis. In 
parallel, antigens or molecules causing injury and inflammatory responses in renal tubular 
cells, initiate tubulointerstitial nephritis, ultimately resulting in tubulointerstitial fibrosis 
[32]. 
 
As previously stated, any disease that causes progressive kidney injury may lead to renal 
fibrosis. The histopathology of tubulointerstitial fibrosis is characterized by the deposition of 
ECM in the interstitium associated with inflammatory cell infiltration, tubular cell damage, 
fibroblast activation, and rarefaction of the peritubular microvasculature [41]. Collectively, 
the fibrotic pattern is determined by the cells that are involved. However, glomerular and 
tubular fibrotic processes can’t be entirely separated. Both processes can result in 
progressive kidney disease. Regardless of the nature of the initial renal injury, progressive 
tubulointerstitial fibrosis is the final common mechanism of all chronic kidney disease [42]. 
In primary glomerulopathies, where the injury by definition is glomerular, histological 
evidence of  tubulointerstitial fibrosis has more prognostic value than does glomerular 
pathology [43]. Once renal fibrosis supervenes, progressive functional decline occurs, which 
relentlessly progresses leading to dialysis or renal transplantation. 
 
2.1.3 ECM in renal fibrosis 
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2.1.3.1 ECM and ECM components 
The ECM is a three-dimensional, non-cellular structure that provides structural support for 
organs and tissues and for all cell layers in the form of basement membranes and for 
individual cells as substrates for cell motility [44]. In mammals, the ECM consists of around 
300 proteins, known as the core matrisome, which consists of 43 collagen subunits, 36 
proteoglycans (PGs) and ~200 complex glycoproteins [45]. Those components can be 
divided into two main types with regard to their location and components. One of the types 
is known as the interstitial connective tissue matrix, providing structural scaffolding for 
tissues. The other type is the basement membrane which separates the epithelium from the 
surrounding stroma [46].  
 
Collagens are the main structural proteins of the ECM and are classified into fibrillar (collagens 
I, III, V and XI) and non-fibrillar forms. Those collagen fibrils provide tensile strength to the 
ECM. PGs, such as aggrecan, versican, perlecan and decorin, fill the extracellular interstitial 
space and promote hydration and therefore regulates stiffness of the ECM by sequestering 
water within the tissue [46]. Glycoproteins, such as laminins, elastin, fibronectins, 
thrombospondins, tenascins and nidogen, have diverse functions, including acting as ligands 
for cell surface receptors and small protein fragments released after proteolysis [46]. ECM 
remodelling occurs in response to signals transmitted by known ECM receptors (such as 
integrins), ECM-modifying proteins (such as matrix metalloproteinases (MMPs)) or 
extracellular/cellular tension. The latter is also regulated by ECM remodelling. Cells which 
interact with the ECM not only detect the composition and stiffness of their substrates but 
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their geometry, which trigger different signalling pathways. Imbalance between ECM 
degradation and assembly leads to organ fibrosis, which to date is not reversible. 
 
2.1.3.2 ECM in renal fibrosis 
Accumulation of ECM is considered as the fundamental to the process of fibrogenesis. The 
ECM is known to regulate cell behaviour. The ECM, which was previously thought to have a 
static structure, is now recognised to be constantly undergoing remodelling.  However, 
recent data has proposed that ECM is not only the end consequence of injury but also 
contributes to promoting the fibrotic response. Tissue stiffness induced by over-production 
of the ECM and impaired hydration activates profibrotic growth factor-like TGF-β in a yes-
associated protein (YAP) / transcriptional co-activator with PDZ-binding motif (TAZ)-
dependent pathway, which, in turn, promotes further tubular injury by increasing the 
diffusion distance of oxygen, resulting in increased hypoxia [47, 48]. 
 
By definition, fibrosis correlates with changes in the matrix in both quantitative and 
qualitative manners [49]. In renal fibrosis, the interstitium of the fibrotic kidneys fills with 
fibrillar type I and III collagens [50]. Therefore, type I and III collagens are wildly used as  
hallmarks of renal fibrosis, which can be measured by the techniques including 
immunohistochemistry, trichrome and periodic acid–Schiff and Sirius Red with and without 
polarization[51-53]. Type I collagen is well recognised to be a cause of pathological fibrosis 
but usually, deposits later in the fibrotic process in relatively low amounts. In contrast, type 
III collagen has much more abundant expression [54]. Of note, collagen III morphometry and 
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a visual assessment of trichrome-stained slides have been shown to be efficient and 
reproducible in the assessment of kidney fibrosis and demonstrate correlation with kidney 
function [55] (as shown in Table 2.2 and Table 2.3).  
 
Table 2.2 Correlation of percentage of fibrosis measurements between techniques [55].  
 
Table 2.3 Correlation of renal function with percentage of fibrosis measured by each 
technique [55].  
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Increased thickness of the glomerular basement membrane (GBM) has also been observed 
early in the development of diabetic nephropathy [56]. The specialized GBM  is comprised 
primarily of non-fibrillar collagen ie. collagen IV [57-59]and laminin [60] which is the most 
abundant non-collagenous glycoprotein of basement membranes [61]. Increased 
accumulation of glomerular matrix components leads to glomerulosclerosis and albuminuria 
[62], but as discussed above, tubulointerstitial fibrosis correlates more with functional renal 
decline [43]. 
 
2.1.3.3 ECM breakdown by proteases 
The appropriate and regulated balance of synthesis, degradation and remodelling of ECM in 
the kidney is key to avoiding renal fibrosis as a consequence of injury. A variety of enzymes 
can remodel the matrix, of which the most important are the matrix metalloproteinases 
(MMPs) [63]. MMPs are a large family of proteinases, which play a fundamental role in 
degrading ECM and multiple cellular processes, such as releasing tissue-bound fibroblast 
growth factor (FGF) and vascular endothelial growth factor (VEGF) and regulating 
inflammation [64]. To date, there are 28 MMP genes having been identified in humans, and 
most of them are multidomain proteins [65].  
 
In turn, MMP activity is regulated in various ways, of which the most investigated is tissue 
inhibitors of metalloproteinases (TIMPs). TIMPs bind with MMPs and inhibit or modify their 
function [66]. Of note, in addition to the findings shown in Table 2.4, an early increase in 
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TIMP 1 and -3 expression and activity and a decrease in MMP-1 and -9 activity have been 
associated with the development of tubulointerstitial fibrosis in rats and humans [67-70]. 
These observations indicate upregulated ECM deposition following injury, but decreased 
degradation, accelerating the progression of tubulointerstitial fibrosis at a later period [71].  
 
Table 2.4 MMP/TIMP Mouse Models in Renal Pathophysiology. The generation of 
MMP/TIMP knockout mice knockout mice has advanced the understanding of the role of 
MMPs/TIMPs in AKI/CKD mouse models [72]. 
Abbreviations: MMP, matrix metalloproteinase; TIMP, tissue inhibitors of 
metalloproteinase. 
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2.2 Cells and signalling pathways in renal fibrosis  
2.2.1 Fibroblasts in renal fibrosis 
Fibroblasts are mesenchymal cells, phenotypically showing a spindle-shaped morphology 
and present in all tissues. They are the key to the structure and function of the ECM. They 
maintain tissue architecture by synthesising ECM proteins, as well as proteolytic enzymes 
and inhibitors [73]. Depending on the anatomical site and the degree of activation, 
fibroblasts exhibit high heterogeneity. Compared with other tissues, the normal renal cortex 
has a lower number of fibroblasts, which are concentrated in perivascular or peritubular 
areas. Unlike myofibroblasts, these cells are vimentin positive but not positive for α-smooth 
muscle actin (α-SMA) staining [73-75], suggesting that in a resting state they do not acquire 
a myofibroblastic phenotype. 
 
It is clear that the number of fibroblasts increase in disease states and differentiate into 
myofibroblasts, which may be directed by various cytokines, such as TGF-β1 [73]. However, 
the origin of resident fibroblasts in renal cortex remains largely unknown. Some evidence 
suggests that bone marrow-derived fibroblasts make up 12% of the population in the 
normal kidney interstitium [76] but increases to 30% in the context of disease [77]. It is also 
proposed that resident interstitial fibroblasts can originate from uninduced mesenchyme in 
the embryonic kidney [78]. The source of both resident and accumulating renal fibroblasts 
has been the subject of considerable debate, which to date has not been definitively 
resolved.  
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2.2.2 Myofibroblasts in renal fibrosis  
Myofibroblasts are terminally differentiated cells with an increased capability of producing 
matrix production, which in turn promotes ECM accumulation in fibrosis. Myofibroblasts are 
rarely found in normal tissue. They are contractile cells displaying many of the 
morphological features of smooth muscle cells with an abundant expression of α-SMA, 
which is integrated into stress fibres and elevate the contractile activity of cells [73, 79-81]. 
 
In the normal tissue repair process, myofibroblasts appear but shortly thereafter undergo 
apoptosis. Under pathological situations, myofibroblasts can be induced and sustained by a 
number of growth factors including TGF-β and platelet-derived growth factor and enhanced 
signalling through the Wnt pathway (PDGF) β [82-85].  
 
Given that the myofibroblast is well recognized as a key producer of ECM, the mechanism 
behind myofibroblast persistence in the kidneys of patients with CKD may be of key 
importance in studying the fibrotic response. Numerous investigations have been conducted 
on the origin of renal myofibroblasts. Previous work proposed that the proximal tubular 
cells (PTCs) can transform into interstitial myofibroblasts due to a process of epithelial-
mesenchymal transition (EMT) [76]. Alternatively, or in addition, resident fibroblasts and/or 
pericytes may serve as the likely precursor to the myofibroblasts [86]. Further studies have 
also demonstrated inflammatory cells and bone-marrow derived fibrocytes may also 
transdifferentiate into myofibroblasts [7, 87, 88]. As alluded to above, the concept of EMT 
and endothelial to mesenchymal transition (Endo MT), has waxed and waned for over 20 
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years [89, 90]. By definition, EMT and endoMT refer to epithelial or endothelial cells 
undergoing morphological changes following injury. In this process there is a loss of 
epithelial or endothelial characteristics and acquisition of fibroblast markers (fibroblast-
specific protein (FSP), vimentin and α-SMA) [76, 91-93]. Consequently, these cells start to 
function as (myo)fibroblasts in the tubulointerstitium with the secretion of stress fibres and 
unregulated ECM production.  
 
To date, it is well accepted that α-SMA is the best available marker to identify activated 
myofibroblasts. However, recent literature suggested many matrix-producing cells do not 
always express α-SMA [94, 95]. Hence, the origin of renal myofibroblasts during ECM 
expansion in CKD is still under debate. 
 
2.2.3 Inflammatory cells in renal fibrosis 
Cells infiltrating the renal interstitium have long been believed to play a major role in the 
initiation and progression of tubulointerstitial fibrosis. This is because the degree to which a 
number of cell types, including macrophages, dendritic cells (DCs), T cells and natural killer 
(NK) cells accumulate in the renal interstitium parallels the extent of fibrosis. Among all the 
cell types, the macrophage is the cell type in most models of CKD that is highly associated 
with tubulointerstitial fibrosis and poor renal outcomes [96, 97]. Blocking the function of 
macrophages either genetically or pharmacologically attenuates renal fibrosis in rodent 
models of unilateral ureteral obstruction (UUO) and diabetic nephropathy [98-100], which 
further suggests macrophages have a key role in the development of renal fibrosis. 
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Macrophages have been demonstrated to be a crucial source of MMP-9 in a late-stage UUO 
model [101], which indicates a controversial or perhaps a dual function of macrophages that 
may be dependent on the activation into an M1 or M2 phenotype, which is often context 
dependent [102, 103]. Thus, the macrophage-derived MMPs in CKD may need further 
investigation since the function of some MMPs differs in different CKD model and 
depending on the phase of injury. Furthermore, the macrophage has a key role in 
independent innate and adaptive immune pathways that further direct the injury response 
to repair or fibrosis.  
 
2.2.4 TGF-β1 
2.2.4.1 Overview of TGF-β1 
TGF-β is the prototype of a family of secreted polypeptide growth factors. Three isoforms of 
TGF-β have been identified in mammals, including TGF-β1, TGF-β2 and TGF-β3 [104]. All 
three TGF-β isoforms firstly bind with TGF-β receptor (TGFR) 2 as an active form 
(homodimers) and then activates TGFR1 to initial receptor signalling [105]. After 
synthesizing in a precursor form, TGF-β is cleaved to release the latency associated peptide 
(LAP), which binds to the TGF-β homodimer to promote the formation of the latent TGF-β 
binding protein (LTBP) [106]. However, at this stage, the TGF-β/LAP/LTBP complex remains 
inactive. To release active TGF-β in the ECM, one or more of a wide range of proteases 
including plasmin, matrix metalloproteinase (MMP) 2 and MMP9, thrombospondin, 
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integrins and the cationic independent mannose 6 phosphate receptor are needed to cleave 
the TGF-β complex  into the active component [107]. 
 
It is well accepted that overexpression of active TGF-β1 induces a fibrotic response in 
multiple organs, including the kidney [108]. TGF-β1 is a well-characterised key mediator in 
the pathogenesis of tubulointerstitial fibrosis, due to its direct and indirect effect on various 
cells types [109-111]. The direct action of TGF-β1 transition of cells to a fibroblastic 
phenotype as described above and proliferation, migration and synthesis of profibrotic 
proteins, such as collagens and fibronectin [112-114]. TGF-β1 can also induce an indirect 
fibrotic response, via accelerating apoptosis of resident healthy cells and promoting resident 
and infiltrating cells to increase ECM deposition [115-117]. Inhibiting TGF-β1 in animal 
models of kidney disease attenuates fibroblast activation and ECM accumulation [118-121]. 
However, targeting the entire spectrum of actions of TGF- β1 in preventing renal disease has 
not been fruitful in  that TGF-β1-specific, humanized, neutralizing monoclonal antibody 
added to RAAS inhibitors failed to slow progression of diabetic nephropathy [122]. 
 
2.2.4.2 TGF-β-Smad pathway 
Smads are identified as the intracellular mediator of TGF-β1. Smads separate into different 
classes with regards to their functions: two TGF-β receptor-regulated Smads (R-Smad) 
(Smad2 and Smad3), three bone morphogenetic protein (BMP) R-Smads (Smad1, Smad5, 
and Smad8) , one common mediator Smad (Co-Smad) (Smad 4) and two inhibitory Smads (I-
Smad) (Smad 6 and Smad 7) [123, 124]. TGF-β signalling is initiated with activation of the 
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receptor and R-Smad phosphorylation, followed by translocation of R-Smad/Co-Smad 
complex into the nucleus to regulate gene transcription [125]. By contrast, I-Smads can 
antagonize the activity of the R-Smads and prevent the phosphorylation of R-Smads [123] 
(Figure 2.2). 
 
 
Figure 2.2 TGF-β-Smad pathway. TGF-β binds to the primary TGF-β receptor type II (TGFR2), 
which is a constitutively active serine/threonine kinase that recruits receptor type I (TGFR1) 
to the complex. Subsequent transphosphorylation and activation of TGFR 1 by TGFR2 allows 
the TGFR1 kinase to phosphorylate selected Smads, which are inhibited by the so-called 
inhibitory Smads (Smad6 or Smad7). These receptor-activated Smads (R-Smads, e.g. 
Smad2/3) then form active complexes with the common Smad4, which translocate into the 
nucleus, where they regulate transcription of certain target genes. In addition, the activated 
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receptor complex activates non-Smad signalling pathways, such as Ras, ERK, JNK, p38, RhoA 
and PI3K [9]. 
Abbreviations: ERK, extracellular-signal-regulated kinase; JNK, c-Jun N-terminal kinase; PI3K, 
phosphoinositide 3-kinase. 
 
2.2.4.2.1 R-Smads 
Among R-Smads, it is increasingly reported that BMP R-Smads (1, 5, 8) are involved in the 
development of kidney and renal cell cancer [126-128]. Some studies have reported that the 
BMP-7-Smad1/5/8 pathway contributes to ECM deposition in the kidneys of UUO rats [129] 
and activin receptor-like kinase (ALK)-1 /Smad1/5 pathway may influence ECM protein 
expression in several cell types, such as rat myoblasts, hepatocytes and human 
chondrocytes [130]. However, the role of BMP R-Smads in fibrotic disorders is still unknown. 
 
It is well demonstrated that Smad2 and Smad3 are extensively activated in the  fibrotic 
response induced by TGF-β1 in various animal models and human kidney disease, including 
diabetic [131-135] and obstructive nephropathy [136-140], remnant kidney disease [141, 
142], hypertensive nephropathy [143], drug-associated nephropathy, and immunologically-
mediated glomerulonephritis [144, 145]. The binding of TGF-β1 to TGFR2 activates the 
TGFR2 kinase and phosphorylates Smad2 and Smad3 [146]. TGF-β/Smad3 signalling 
mediates transcription of multiple downstream genes, such as the collagen chains ColIa1, 
ColIa2, ColIIIa1, ColaVa2, ColVIa1 and ColVIa3, and TIMP-1 [147], suggesting a critical role of 
24 
 
Smad3 in fibrosis. In addition, it is increasingly reported that deletion of Smad3 in mice 
suppresses fibrosis in rodent models of kidney disease [133, 137, 148]. 
 
Relative to Smad3, the function of Smad2 in renal fibrosis is not fully elucidated. Because of 
the unavailability of Smad2 knock out (KO) mice, conditional kidney tubular epithelial cells 
Smad2 KO mice have been generated by crossing the Smad2 floxed mouse with the kidney-
specific promoter (Cadherin 16)-driven Cre transgenic mouse [149]. Unexpectedly, deletion 
of Smad2 in tubular cells significantly enhances fibrosis, with an associated elevated Smad3 
signalling in the UUO mouse model [150]. It is commonly believed that Smad2 may inhibit 
the phosphorylation of Smad3 when exposed to TGF-β1. It is also possible that Smad2 and 
Smad4 may reduce phosphor-Smad3 nuclear translocation and then binding to its target 
genes. Consistent with this view, a reduction in Smad 2 has been shown to increase 
activation of Smad3 and promote collagen expression in response to fibrotic mediators 
[132, 141, 143, 148, 151]. Therefore, Smad2 and Smad3 may have distinct roles in mediating 
the fibrosis upon exposure to TGF-β1. 
 
2.2.4.2.2 Co-Smad4 
Smad4 plays a key role in nucleocytoplasmic shuttling of Smad2/3 and Smad1/5/8 into the 
nucleus [152]. Loss of Smad4 has been demonstrated to inhibit TGF-β1 induced ECM 
accumulation in mesangial cells. In addition, specific deletion of Smad4 from renal tubular 
cells alleviates renal fibrosis in a mouse model of UUO by suppressing Smad3 function [153]. 
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2.2.4.2.3 I-Smads 
Smad 6 and Smad7 act as inhibitory mediators in the TGF-β/Smad pathway via a negative 
feedback loop that prevents the phosphorylation of Smad2 and 3 [154-157]. However, the 
phosphorylation of I-Smads remains largely unknown. Despite the phosphorylation sites, the 
importance of Smad6 for cellular signalling remains unclear [158-160]. 
 
TGF-β induces Smad7 transcription but then promotes its degradation by initiating the 
Smad3-dependent Smurfs/Arkadia-mediated ubiquitin-proteasome degradation pathway 
that degrades Smad7 protein [156, 157, 161, 162]. Furthermore, deletion of Smad7 
promotes fibrogenesis in a number of mouse models, including UUO [140], diabetic [135] 
and hypertensive nephropathy [163]. Collectively these studies suggest that activation of 
Smad3 is tightly associated with the degradation of Smad7. An imbalance in the activity of 
Smad3 and Smad7 has been reported to be a major mechanism in fibrogenesis. 
 
2.2.4.3 Non-Smad pathways  
In addition to Smad mediated signalling cascades, TGF-β can independently and directly 
activate other pathways, such as Ras/Raf/extracellular-signal-regulated kinase (ERK)/ 
mitogen-activated protein kinase (MAPK) pathways, c-Jun N-terminal kinase (JNK), p38 
MAPK signalling and Rho-like GTPase signalling pathways [9]. TGF-β can induce 
phosphorylation of tyrosine residues on TGFRs (I and II) and recruit ERK through Ras, Raf 
and their downstream MAPK cascades. In this thesis, I specifically focussed on ERK as it 
regulates target gene transcription through its downstream transcription factors in 
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conjunction with Smads to control EMT [164]. ERK can also regulate the activity of R-Smads, 
including Smad1, Smad2 and Smad3 [165-168]. Moreover, ERK is involved in the 
autoinduction of TGF-β1 via distinct transcriptional and translational mechanisms in tubular 
epithelial cells [169]. These studies suggest a dominant role of ERK in the non-Smad 
mediated transduction of TGF-β1. 
 
The Rho-like GTPases, including RhoA, Rac and Cdc42, play crucial roles in controlling 
dynamic cytoskeletal organization, cell motility, and gene expression through a variety of 
effectors [170]. In addition to MAPK pathways, RhoA is an important regulator, which can be 
activated by TGF-β via either Smad-dependent or independent pathways to induce stress 
fibre formation during EMT [171, 172].  
 
JNK and p38 MAPK pathways are the best characterized non-Smad pathways involved in 
renal fibrosis. TGF-β can rapidly activate JNK and p38 MAPK via MAPK kinase (MKK) 4 and 
MKK 3/6, respectively [173-179].  Activated JNK/p38 acts in conjunction with Smad2/3 to 
regulate apoptosis and EMT by controlling the activities of downstream transcription factors 
[179-185]. JNK can also regulate Smad 3 activity directly by phosphorylation [185, 186].  
 
2.2.5 Pyrin domain-containing protein 3 (NLRP3) inflammasome 
Inflammation is integral to most kidney diseases. Adaptive immunity is associated with 
kidney disease where foreign antigens incite injury (e.g. in post-infectious 
glomerulonephritis) or autoantigens (e.g. in anti-glomerular basement membrane 
27 
 
glomerulonephritis, renal transplantation, IgA nephropathy). Innate immunity is responsible 
for antigen-independent inflammation [187]. Increasing research interest has focused on 
innate immune responses during renal infection, toxic, ischemic, and traumatic kidney 
injury[187]. However, evidence also exists that innate immunity contributes to CKD 
including diabetic nephropathy [188] and polycystic kidney disease [189]. Hence the 
importance of innate immune response in the progression of CKD is increasingly being 
investigated. 
 
Innate immune response is initiated by several classes of pattern recognition receptors 
(PRRs), such as TLRs and nucleotide-binding and oligomerization domain (NOD)-like 
receptors (NLRs), along with inflammasomes leading to the early innate immune response 
[12]. The NLRP3 inflammasome consists of NLRP3 protein, adapter protein apoptosis-
associated speck-like protein (ASC) and procaspase-1[190]. It is well established that the 
NLRP3 Inflammasome plays a vital role in innate immunity. NLRP3 inflammasome activity 
can be induced in response to immune activators such as pathogen-associated molecular 
patterns (PAMPs), danger-associated molecular patterns (DAMPs), other exogenous 
invaders or environmental stress. Induced inflammasome complex triggers the 
transformation of procaspase-1 to caspase-1, as well as the conversion of interleukin (IL) -1β 
and IL-18 into a mature form that facilitates the biological function of inflammasome (Figure 
2.3) [191, 192].  
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Figure 2.3 Schematic illustration of the NLRP3 inflammasome activation. Upon exposure to 
PAMPs or DAMPs, TLRs are phosphorylated and subsequently activate NF-κB. In the nucleus, 
NF-κB promotes the transcription of NLRP3, pro-IL-1β, and pro-IL-18, which, after 
translation, remain in the cytoplasm in inactive forms. Thus, this signal (depicted in red as 
“Signal 1”) is a priming event. A subsequent stimulus (shown as “Signal 2” in black) activates 
the NLRP3 inflammasome by facilitating the oligomerization of inactive NLRP3, ASC, and 
procaspase-1. This complex, in turn, catalyzes the conversion of procaspase-1 to caspase-1, 
which contributes to the production and secretion of the mature IL-1β and IL-18 [192]. 
Abbreviations: NLRP3, pyrin domain-containing protein 3; PAMPs, pathogen-associated 
molecular patterns; DAMPs, danger-associated molecular patterns; TLRs, Toll-like receptors; 
NF-κB, nuclear factor kappa light chain enhancer of activated B cells; IL, interleukin; ASC, 
apoptosis-associated speck-like protein; ROS, reactive oxygen species. 
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To date, the cell-specific expression of the components of NLRP3 inflammasome within the 
kidney remains only partially elucidated. Renal immune cells, such as DCs and macrophages, 
express all NLRP3 components. Some non-immune renal parenchymal cells don’t express all 
the components of the inflammasome. For example, mesangial cells can express and release 
IL-18 but not IL-1β. As such, the canonical effect of the NLRP3 inflammasome in renal non-
immune cells remains uncertain. Of note, expressing and releasing of IL-18 and IL-1β has 
been observed in tubular epithelial cells, indicating the potential function of NLRP3 in 
tubular injury [193]. 
 
Given that the NLRP3 inflammasome is a key mediator in the inflammatory response, 
NLRP3-deficiency has been reported to protect mice from ischemic acute tubular necrosis 
[194, 195]. However, consistent results have not observed in ASC deficiency animals [195]. 
Similarly, blockade of IL-1 or IL-18 has had no effect on ischemic kidney injury [195, 196]. 
Thus, renoprotection dependent on IL-1 or IL-18 deficiency has not been consistently 
reported. Conversely, NLRP3 deficiency has been reported to reduce renal ischemia-
reperfusion injury in all studies [195-199], suggesting the NLRP3 inflammasome has non-
canonical effects independent of IL-1β or IL-18. These non-canonical effects of NLRP3 
remain under debate but some studies have suggested it could be related to TGF-β 
signalling within tubular epithelial cells[193]. The NLRP3 expression can be induced by TGF-β 
in a Smad3-dependent manner and is required for TGF-β-mediated Smad2/3 
phosphorylation. This function of NLRP3 seems to correlate with EMT, which is highly 
associated with interstitial fibrosis in CKD [200, 201].  
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2.2.6 Toll-like receptors (TLRs) 
TLRs are a conserved family of pattern recognition receptors which share the same 
cytoplasmic domain as the toll-IL-1 receptor (TIR) and similar activation pathways, including 
identified 11 human and 13 mouse TLRs [202]. In response to PAMPs or DAMPs, TLRs 
activate host cell inflammatory response. After activation, TLRs recruit differential adapter 
molecules and catalyze the downstream signalling pathway including myeloid differentiation 
primary response protein 88 (MyD88)-dependent and independent, and thus result in the 
release of cytokines and chemokines (Figure 2.4) [203, 204]. 
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Figure 2.4 TLRs pathway. All TLRs (except for TLR3) signal through the adaptor protein 
MyD88 to activate nuclear factor (NF)-κB and mitogen-activated protein kinases for the 
induction of proinflammatory cytokines. TLR3 signals through TRIF /TICAM1. Other TLR 
adaptors include TRIF, TIRAP, and TRAM [205, 206]. 
Abbreviations: MyD88, myeloid differentiation primary response protein 88; TRIF, TIR-
domain-containing adaptor-inducing interferon-β; TICAM1, TIR-containing adaptor molecule 
1; TIRAP, TIR-domain-containing adaptor protein; TRAM, TRIF-related adaptor molecule; IKK, 
inhibitor of κB-kinase; IRAK, interleukin-1 receptor-associated kinase; NEMO, NF-κB 
essential modulator; pDCs, plasmacytoid dendritic cells; RIP1, receptor-interacting protein-
1; TAB-1, TAK1-binding protein; TAK, TGF-β activated kinase; TRAF, tumour necrosis factor 
receptor-associated factor. 
 
TLRs are expressed in a number of cells within the kidney, such as DCs [207, 208], 
lymphocytes [209], macrophages [210-212], intrinsic renal cells [213], podocytes [213], 
mesangial [214, 215], endothelial [216-218] and tubular epithelial cells [219]. Specifically, 
interstitial and glomerular macrophages express TLR1, 2, 4, and 6, and DCs express TLR4, 7, 
8, and 9. TLR2 and TLR4 are upregulated in monocytes as well as in tubular cells and 
myofibroblasts in models of renal injury stage [206]. To date, most of the TLRs studies on 
CKD focus on TLR2 and TLR4 (Table 2.5).  
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Table 2.5 TLR2 and TLR4 expression in association with chronic kidney diseases [206]. 
Abbreviations: CKD, chronic kidney disease; DN, diabetic nephropathy; ESRD, end-stage 
renal disease; IgA, immunoglobulin A; TLR, Toll-like receptor; UUO, unilateral ureteral 
obstruction. 
 
TLR signalling, mainly TLR2 and TLR4, is implicated in inflammatory and autoimmune kidney 
disease as well as in non-immune kidney disease, including ischemia/reperfusion (I/R) injury 
[220, 221], UUO [222-224], tubulointerstitial nephritis [225], nephrotoxicity [226-228] and 
diabetic nephropathy [229, 230]. There is strong evidence implicating TLR2 and 4 as 
mediators of inflammation in the non-immune UUO model of renal injury. TLR2 was 
markedly upregulated in the kidney subjected to UUO, as early as 2 days after surgery [231, 
232].  Evidence from TLR2-/- mice studies supports that TLR2 initiates renal inflammation 
during the early stage of UUO [231]. However, deletion of TLR2 did not change the ECM 
accumulation in this model [231], which is supported by independent reports that the 
development of renal fibrosis in the UUO model  is independent of TLR2-MyD88 signalling 
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[232]. Similarly, renal TLR4 expression was found to be progressively elevated in the UUO 
model [224]. In contrast to the TLR2-/- mice, TLR4 -/- mice had less renal fibrosis with less α-
SMA and fibroblast accumulation [224], suggesting that TLR2 and TLR4 may have distinct 
roles in the development and progression of renal pathology.   
 
Renal biopsies of patients with diabetic nephropathy  show a significant up-regulation of 
TLR2 [230] and TLR4 [229] in the tubules compared to those from normal kidneys. In mouse 
models of diabetic nephropathy, TLR2 plays a pro-inflammatory role, which is consistent 
with the role demonstrated in the UUO model. Deletion of TLR2 reduced macrophage-
mediated inflammation, albuminuria and podocyte loss in STZ-induced type 1 DM [233]. 
Conversely, TLR4 induces tubulointerstitial fibrosis via increasing the susceptibility of tubular 
cells and myofibroblasts upon TGF-β independent of TGF-β/Smad pathway [222]. 
Additionally, fibrinogen, an endogenous ligand for TLRs, is known to initiate resident 
fibroblast proliferation through the TLR2/TLR4 MyD88/ nuclear factor kappa light chain 
enhancer of activated B cells (NF-κB) pathway in the kidney [223, 234].  
 
Therefore, although TLR2 and TLR4 are often contemporaneously upregulated in multiple 
models of renal disease, they have distinct roles in the development of renal fibrosis. TLR2 
triggers pro-inflammatory responses while TLR4 regulates both pro-inflammatory and pro-
fibrotic pathways (Figure 2.5).  
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Figure 2.5 Role of Toll-like receptor -2 and -4 in renal fibrosis [206]. 
Abbreviations: ECM, extracellular matrix; HMGB1, high-mobility-group box 1; HSPs, heat 
shock proteins; TGF-β, transforming growth factor-β. 
 
2.2.7 Tumour necrosis factor-α (TNF-α) 
TNF-α, produced by various cells including macrophages, mesangial cells and renal tubular 
epithelial cells, stimulates the release of multiple cytokines and contributes to renal fibrosis 
[235, 236]. As the first cytokine to appear in the blood after injury or stress, TNF-α is well 
recognized as an important host defence molecule. The release of other pro-inflammatory 
mediators, such as IL-1 or IL-6, is dependent on the prior release of TNF-α. TNF-α ‘s 
biological function is mediated by binding with two TNF receptors (TNFR)1 and TNFR2, 
which then promotes the downstream generation of inflammatory cytokines [237]. 
 
Elevated TNF-α levels have been observed in various rodent models of kidney disease, such 
as cyclosporine A-induced nephropathy [238], diabetic nephropathy [239, 240], adenine-
induced nephropathy [241]. Moreover, inhibition of TNF-α slows the progression of renal 
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disease, including in diabetic nephropathy [242]. An anti-TNF-α monoclonal antibody has 
been evaluated in Phase II clinical trial (NCT00814255) as an anti-fibrotic agent in patients 
with primary focal segmental glomerulosclerosis (FSGS). Unfortunately, the trial failed to 
recruit sufficient patients to reach a definitive conclusion [235]. Furthermore, in patients 
with type 1 diabetes, the renal functional decline was associated only modestly with total 
TNFα concentration in serum and was unrelated to free TNFα, whilst circulating 
concentrations of TNFR1 and TNFR2 were strongly associated with a risk for the early renal 
decline and remained stable over long periods [243]. Similar results have also been found in 
patients with type 2 diabetes. Elevated TNFR1 and TNFR2 were associated with an increased 
risk for progression of functional renal decline in patients with diabetic kidney disease [244].  
 
2.3 Animal models of renal fibrosis 
To study the mechanisms and pathogenesis of renal fibrosis and provide an avenue for 
future treatment, many animal models have been developed, each of those mirrors various 
elements of human CKD. However, each model has strengths and disadvantages. There is no 
perfect model which can exactly mimic all characteristics of human renal fibrosis.  
 
2.3.1 FA nephropathy 
It is well known that high dosages of folic acid given i.p. in mice induces tubular necrosis by 
direct tubular toxicity, deposition of FA in the tubular lumen, interstitial oedema, oliguria 
and proliferation of interstitial connective tissue [245]. Thus, FA induces renal injury via two 
mechanisms: direct nephrotoxicity and the deposition of intratubular FA crystals, resulting 
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in intrarenal obstruction. To reduce the deposition of FA and separate the nephrotoxic and 
obstructive effects of FA, the alkalinity of the urine is increased with co-administration of 
sodium bicarbonate (FA in 0.3 M NaHCO3 vehicle) to decrease intratubular crystal formation 
when using this model [246-248].  
 
FA leads to acute injury (1-14 days) [249] and patchy interstitial fibrosis in the chronic phase 
(28-42 days) [250]. Because of the varying pathological change in the kidney at different 
time points, the FA-induced kidney injury model is widely used for studying both acute 
kidney injury [251, 252] and chronic kidney fibrosis [248]. In addition, compared with the 
UUO model, which by virtue of it being a unilateral renal injury doesn’t result in significant 
renal impairment, renal function correlates with the development of CKD [253]. Having said 
this, it is reported that after FA injection in rats, plasma creatinine and blood urea nitrogen 
(BUN) peak at 24 hours and plateau up to day 6 and decrease thereafter [254]. Hence 
assessment of kidney function in the acute phase is indicative of acute kidney injury but is 
less reflective of renal pathology in the chronic phase. This is consistent with serum markers 
of renal function in humans where considerable renal pathology can exist before serum 
markers become abnormal [255].  
 
2.3.2 Streptozotocin (STZ)-induced diabetic nephropathy (DN) 
A reliable animal model of diabetic renal injury is a useful tool to investigate the underlying 
mechanism of diabetic nephropathy. It is well studied as diabetic kidney disease is the 
commonest cause of CKD and hence a rodent model of DN is highly relevant to human 
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disease. STZ is an analogue of N-acetylglucosamine (GlcNAc), which is transported into 
pancreatic β cells. STZ selectively inhibits the activity O- GlcNAcase in β cells, causing O-
glycosylation of intracellular proteins, β -cell apoptosis and ensuing insulin deficiency [256].  
 
Using STZ to establish type 1 diabetes has been shown to develop modest elevations in 
albuminuria and serum creatinine and histological lesions reflective of diabetic nephropathy 
18-24 weeks following the induction of diabetes [257, 258]. There are two approaches to 
induce diabetic nephropathy using STZ in mice. One is a low-dose injection of STZ (55 
mg/kg) IP for five consecutive days. One week after the final STZ injection, over 90% of STZ- 
treated mice have a non-fasting blood glucose of more than 15 mmol/L.  The second model 
uses a single high dosage of STZ (≥200 mg/kg) or a two-dose regimen of STZ (2 x 100–125 
mg/kg) given on consecutive days. STZ-induced diabetic mice may have significant weight 
loss, which may due to the catabolic effects of insulin deficiency, severe hyperglycaemia and 
the volume depletion associated with osmotic diuresis. Low dose insulin treatment may be 
required to stabilise the catabolic effects without reversing hyperglycaemia [259]. Of note, 
at high doses, STZ has non-specific cytotoxicity to kidney, which can result in acute kidney 
injury in mice and rats [260, 261], thus makes using this model less reflective of pure 
diabetic nephropathy. Hence the low dose model is preferred. 
 
The use of STZ is a robust method for inducing diabetes in rodents. However, all animal 
models of diabetic nephropathy vary in the degree to which they resemble human disease 
[262]. Furthermore, the susceptibility to induce diabetes and diabetic nephropathy differs in 
different strains of mice with different genetic backgrounds [263]. For example, C57BL/6 
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mice are the most commonly used strain of mice used experimentally for a number of 
different diseases. Compared with other strains, C57BL/6 mice are resistant to the 
development of renal injury induced by diabetes. C57BL/6 diabetic mice show mild to 
moderate albuminuria and display early nephropathic changes at 6 months after the 
induction of diabetes [264].  
 
Endothelial dysfunction has been demonstrated as a crucial part in the progression of DN 
[265, 266]. Nitric oxide (NO) produced by NO synthase (NOS), mainly endothelial nitric oxide 
synthase (eNOS) in renal vasculature, contributes to the endothelial dysfunction in diabetes 
[267, 268]. Fundamentally, DN is a microvascular disease. Multiple studies have reported 
that the eNOS-/- diabetic mice display advanced nephropathic changes the features similar 
to human DN compared to its wild-type mouse model [269, 270]. These studies clearly 
defined eNOS-/- diabetic mouse model a robust animal model of DN. Thus, the genetic 
background and strain of mice are necessary to consider when using an insulin-deficient 
STZ-induced model. 
 
2.3.3 Adenine 
CKD induced by adenine has been shown to be a reliable model of CKD in mice and rats. 
Adenine is metabolized to 2,8-dihydroxyadenine, which precipitates and produces tubular 
crystals within the kidney [271-273]. Adenine can be administrated by oral gavage or diet.  It 
is reported that oral dosing with adenine at 50 mg/kg for 28 days is suitable to induce a 
stable anemia associated with CKD in mice [274]. Furthermore, the administration of a 
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0.75% adenine diet in rats for 4 weeks results in irreversible chronic renal failure, which 
reflects CKD seen clinically [275]. Of interest, different manifestations of CKD can be 
observed using different dietary concentrations of adenine (Table 2.6) [276].  
 
Table 2.6 Comparison of CKD manifestations with different adenine doses [276]. 
 
2.3.4 5/6 Nephrectomy 
5/6 nephrectomy mimics progressive renal failure after the loss of renal mass in human. It is 
essentially a hyperfiltration model of the renal disease. To induce this model, there are 
different ways to ablate 2/3 of the remaining kidney after removing one kidney [277]. One 
approach often used in rats is ligation of the branches of the renal artery after contralateral 
uninephrectomy. However, this approach is not usually suitable in mice due to limited renal 
artery branching. Hence an alternative method is to remove approximately 50% of the 
remaining kidney by polar excision 1-2 weeks after uninephrectomy. The final approach is to 
ligate one or more branches of the mouse renal artery, with cauterisation performed as 
needed to remove additional renal mass to establish the model.  
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The ligation results in more severe proteinuria and hypertension than those with excision, 
which may be due to the upregulated RAAS observed with regional ischemia. Proteinuria 
develops from week 2 and reaches 200-600mg/24h. Glomerular hypertrophy occurs in the 
acute phase (0-4 weeks). After 8 weeks, about up to 20% glomeruli develop mesangial 
expansion and focal and segmental glomerular sclerosis, associated with early interstitial 
fibrosis and tubular atrophy. By 12 weeks, universal glomerulosclerosis and tubulointerstitial 
fibrosis appear [253, 278]. 
 
2.3.5 Ureteric ureteral obstruction (UUO) 
The UUO model is widely used to study mechanisms of tubulointerstitial fibrosis [279-281]. 
UUO induces severe renal injury, characterised by reduced renal blood flow and glomerular 
filtration rate within 24 h, followed by interstitial inflammation (peak at 2-3 days), tubular 
dilation, tubular atrophy and fibrosis within a week. By 2 weeks, the obstructed kidney has 
no function [282]. The model develops interstitial infiltration of macrophages, tubular cell 
death, the phenotypic transition of resident renal cells and severe interstitial renal fibrosis 
with the associated expansion of the ECM.  
 
Complete ureteral obstruction is not a usual cause of human renal disease. However, partial 
obstructive nephropathy is not uncommon. Therefore, models of partial or reversible UUO 
have been developed in the rat and mouse. However, compared to the complete 
obstruction model, renal pathology in the partial or reversible models is variable and 
unpredictable [283]. Thus, the advantage of the complete obstruction model is that it is 
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reproducible, and injury develops within a short time of obstruction. The disadvantages 
include the lack of serum biochemical markers of CKD and given the mechanical nature of 
the injury, pharmacological interventions are unlikely to positively impact on the pathology 
observed. 
 
Compared to other models of progressive renal injury, the chronic phase of the FA model of 
CKD provides a useful tool to study the mechanism of the fibrotic response as well as the 
impact of pharmacological intervention on fibrosis. The low-dose STZ induced diabetic 
model is a reliable and robust model for diabetic study, which is approved by the Animal 
Models for Diabetic Complications Consortium (AMDCC) [284]. Therefore, I chose FA 
nephropathy and the low-dose STZ induced diabetic models for my studies. 
 
2.4 Receptor-interacting serine/threonine-protein kinase (RIPK) 3 
The RIP kinase family contains seven members, each of which contains a homologous kinase 
domain. To date, the functions of RIPKs 4–7 are poorly understood [285]. RIPK2 is a 
mediator of mucosal immunity. Extensive studies have clarified the important molecular and 
physiological roles of RIPK1 and RIPK3 in inflammation and cell death [286, 287].  
 
The RIPK3 gene is located on chromosome 14 in both human and mouse. This gene encodes 
a 518 amino acid (aa) protein with a molecular mass of 57kDa in humans, whereas it 
encodes a 486 aa protein of 53kDa in mice 1-3 (as shown in Figure 2.6). RIPK3 is a 
threonine/serine protein kinase which shares almost 30% identity and 60% with the other 
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two RIP members, RIPK1 and RIPK2 [288, 289]. Compared with RIPK2, RIPK3 and RIPK1 have 
a unique C-terminal RIP homotypic interaction motif (RHIM) [288], which enables homotypic 
protein interactions [290].  
 
To date, several phosphorylation sites of RIPK3 have been identified. Ser227 (Thr231/Ser232 
for mouse RIP3) and Ser199 (Ser204 in mouse) are particularly crucial for the activation of 
its downstream substrate in the necroptosis pathway, mixed-lineage kinase domain-like 
(MLKL) [291-294].  
 
 
Figure 2.6 RIPK3 structure. (a) RIPK3 structure of human RIPK3 (hRIPK3) and (b) mouse RIPK3 
(mRIPK3) [295]. Abbreviations: RIPK3, receptor-interacting serine/threonine-protein kinase 
3; RHIM, RIP homotypic interaction motif. 
 
2.4.1 RIPK3 in necroptosis 
In response to physiological signals and pathological stimuli, cell death is crucial to 
maintaining homeostasis. To date, several types of cell death have been identified. Among 
them, necrosis is a type of cell death characterized by loss of intracellular contents and the 
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triggering of a subsequent inflammatory response. For many years, necrosis was considered 
to be accidental and therefore unregulated cell death [296-299]. The recognition that 
necroptosis is programmed necrosis has provided new insights into necrosis-induced cell 
death. Necroptosis has been well demonstrated to be mediated by the dimerization of 
RIPK1-RIPK3 to form the necrosome with downstream expression of MLKL [300]. RIPK1 and 
RIPK3 both possess RHIM, with bilateral interaction between RIPK1 and RIPK3. 
Subsequently, the necrosome facilitates the aggregation of phosphorylated RIPK3 and 
phosphorylation of MLKL by RIPK3. Phosphorylated MLKL translocates to the cell membrane 
and thus induces necroptosis (Figure 2.7) [301].  Along with the activity of the inhibitors of 
apoptosis protein (IAP) ubiquitin ligases, a death domain (DD) on RIPK1 can also induce the 
adapter Fas-associated protein with death domain (FADD), caspase 8 and the caspase 
paralog cellular FADD-like IL-1β-converting enzyme-inhibitory protein (cFLIP) to the 
necrosome [302-305]. Consistently, in the absence of cIAPs and/or blockade of caspase 8, 
necroptosis will occur [304]. 
 
The cytokine TNF has a key effect on cell death and tissue injury mainly via TNFR1 
associated TNF signalling [297]. TNF is known as a potent inducer of necrosis and apoptosis 
and hence much of the knowledge on necroptosis comes from the studying of TNF [294, 
306, 307]. TNFR1 stimulation induces a different response in cells depending on the cell type 
and pervading inflammatory conditions. For example, for most cells, TNFR1 stimulation 
activates inflammatory pathways via the formation of a membrane-associated protein 
complex (complex I) [297]. In the presence of specific conditions or in certain cells, TNFR1 
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activation can recruit and trigger the necrosome formation and thus induce necroptosis 
(Figure 2.7) [25]. 
 
In addition to TNFR1, there are other death receptors (DRs) of the TNF superfamily, such as 
Fas (also known as CD95 or apoptosis antigen 1), DR3 (also known as apoptosis antigen 3), 
TNF-related apoptosis-inducing ligand receptor 1 (TRAILR1, also known as DR4), TRAILR2 
(also known as DR5), and DR6 [308]. Binding of Fas ligand (FASL) to Fas or TRAIL to TRAILR1 
or TRAILR 2 stimulates the formation of a membrane-associated death-inducing signalling 
complex (DISC) via FADD, resulting in an activation of caspase 8 and subsequent apoptosis. 
In the absence of cIAPs and blockade of caspase 8, these ligands can also induce necroptosis 
[303]. In addition, other receptors including TLRs, NLRs, retinoic acid-inducible gene I (RIG-I)-
like receptors (RGRs), ripoptosome and protein kinase R (PKR) complexes have also been 
demonstrated to initiate necroptosis [14]. 
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Figure 2.7 RIPK1-RIPK3 regulates and integrates necroptotic cell death from multiple 
receptors. Necroptosis can be induced by death receptors including TNFR1 (top left); TLR4, 
via a TRIF-RIPK1-RIPK3 complex (top middle); TLR3, via a TRIF–RIPK1–FADD–cFLIP–caspase-8 
complex (top right); or IFNRs, via a RIPK1-RIPK3 complex (top, middle). These pathways can 
induce the association of RIPK1 with RIPK3 via RHIM-RHIM domain interactions (light blue) 
and phosphorylation of RIPK3, which leads to aggregation of phosphorylated RIPK3 (pRIPK3) 
and phosphorylation of MLKL by RIPK3. Translocation of phosphorylated MLKL (pMLKL) to 
the cell membrane leads to necroptosis, with the release of DAMPs [25]. 
Abbreviations: RIPK, receptor-interacting serine/threonine-protein kinase; TNFR, tumour 
necrosis factor receptor; FADD, Fas-associated protein with death domain; cFLIP, cellular 
FADD-like IL-1β-converting enzyme-inhibitory protein; MLKL, mixed-lineage kinase domain-
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like; IFN, interferon; LPS, lipopolysaccharide; mtDNA, mitochondrial DNA; MCMV, murine 
cytomegalovirus; dsDNA, double-stranded DNA. 
 
As discussed above, necroptosis is a type of regulated necrosis which is mediated by RIPK3, 
RIPK1 and the executor MLKL. However, in contrast to the obligatory involvement of RIPK3, 
RIPK1 is not always required. The M45-mutant strain of murine cytomegalovirus (MCMV) 
infection induces RIPK3 activation in the absence of activation of RIPK1 [309, 310]. There is 
also evidence that the RHIM-containing protein (ICP) 6 protein of herpes simplex virus 1 
recruits RIPK3 directly and independent of RIPK1 [311]. In addition, as shown in Figure 2.8, 
RIPK1 may have dual influences on cell death by both promoting necroptosis and protecting 
cells from death under certain conditions. However, the necroptosis inhibitor Nec-1s, known 
as the RIPK1 inhibitor, has been consistently proven to abolish the RIPK1/RIPK3 necrosome 
formation and following necroptosis in various models and cells [312-314].  
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Figure 2.8 Time of death of mice mutant for genes controlling apoptosis or necroptosis. 
Mouse genotypes are indicated on the left and the length of the line on the right indicates 
how long each genotype survives. Blue lines indicate where death is due to inappropriate 
necroptosis, red lines indicate where death is due to inappropriate apoptosis, and purple 
lines indicate where death is due to apoptosis and necroptosis. Embryos are designated E0 
when a vaginal plug is detected. P0 refers to newborn mice [315]. 
Abbreviations: kd, D161N kinase dead mutant. Cflar encodes c-FLIP (cellular FADD-like IL-
1β-converting enzyme-inhibitory protein). 
 
2.4.2 RIPK3 in inflammation 
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In addition to its functional involvement in necroptosis, under specific conditions, RIPK3 can 
also serve as a pro-apoptosis adaptor, which recruits RIPK1 and FADD to activate caspase 8 
and thus apoptosis. This effect relies on the involvement of caspase 8 when RIPK3 is inactive 
or MLKL is absent [316, 317]. RIPK3 deficient animals develop normally whereas mice 
expressing catalytically inactive RIPK3 D161N died around embryonic day 11.5 from 
unregulated apoptotic injury [316]. Similar effects are observed in a study using compounds 
that selectively inhibit RIPK3 interaction with caspase 8 independent of pro-necrotic kinase 
activity and MLKL [317].   
 
RIPK3 is mainly reported as a regulator of cell death, but recent studies also identify that 
RIPK3 is an important mediator in NLRP3 inflammasome formation [23]. It is well 
documented that elevation of RIPK3 activity induces an increase of phosphorylation of MLKL 
activity, which leads to the NLRP3 activation. Furthermore, increased RIPK3 expression can 
directly promote NLRP3 inflammasome and the associated inflammatory responses 
independent of MLKL [23-27, 318].  
 
2.4.3 RIPK3 in kidney disease 
Given the importance of RIPK3 in inflammation is increasingly recognised, recent studies 
have investigated the role of RIPK3 in kidney disease. The majority of these studies have 
used an acute kidney injury (AKI) animal model [319, 320] or allograft survival after 
transplantation [321]. Lack of RIPK3 protects kidney tubular injury in both sepsis-induced 
AKI [319] and FA-induced AKI [320]. Interestingly, MLKL deficiency aggravates kidney 
49 
 
function associated with amplified histologic damage in the model of FA-induced AKI [320], 
suggesting that the effect of RIPK3 may be independent of MLKL. However, no study has 
assessed the role of RIPK3 in the chronic phase of kidney disease. 
 
A recent report has demonstrated that RIPK3 promotes kidney fibrosis, which is correlated 
with AKT-dependent ATP citrate lyase (ACL) in both the UUO-induced and adenine diet-
induced renal fibrosis. This study, contemporaneously undertaken at the time of my PhD, is 
the first to address the role of RIPK3 in renal fibrosis by mediating survive and proliferation 
of fibroblasts [22]. It needs to be noted that deficiency of MLKL also failed to protect the 
kidney from fibrosis in this study [22].  
 
2.4.4 Pharmacological blockers of RIPK3 
To date, several selective small-molecule compounds have been shown to inhibit RIPK3-
dependent necroptosis [317], providing an impressive toolbox for the investigation of the role 
of RIPK3 in diverse tissues. GSK’872 is the most widely-used cell-permeable inhibitor of the 
RIPK3-selective kinase, with >1,000-fold selectivity over a vast majority of more than 300 
other kinases [322]. GSK’872 binds the kinase domain and inhibits kinase activity with high 
specificity, targeting a broad range of pro-necrotic stimuli [317] and has been used to 
specifically inhibit RIPK3 [22, 322-325].     
 
Compared with GSK’872, dabrafenib is not a selective RIPK3 inhibitor. Previous studies have 
reported that dabrafenib is a RIPK3 inhibitor in various models, including human hepatocytes 
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[326], mouse models of acetaminophen-induced liver injury [326] and ischemic brain injury 
[327]. In addition, dabrafenib is a well-known inhibitor of B-Raf, which suppresses the 
downstream Ras/Raf/ERK/MAPK pathway [328] which has been approved for clinical use for 
the treatment of non-small cell lung cancer expressing B-Raf V600E mutations and in melanoma 
[329]. Inhibition of Raf kinase is known to attenuate renal fibrosis in a rat model of autosomal 
dominant polycystic kidney disease [330]. It is also recognised that transforming growth 
factor beta (TGF-β) 1 can induce Ras/Raf/ERK/MAPK pathways [331], resulting in renal fibrosis. 
Therefore, dabrafenib may show renoprotection in the context of diverse models of renal 
fibrosis.  
 
Collectively, RIPK3 might be a crucial regulator in renal fibrosis via its mediated-necroptosis 
or -inflammation. By using the RIPK3 -/- mouse model in 2 diverse forms of renal disease and 
comparing to the results observed in the dabrafenib treated mice, we considered it would be 
possible to dissect mechanisms of benefit of RIPK3 inhibition and conversely benefit of 
dabrafenib independently of RIPK3. 
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Chapter 3 Methodology 
3.1 Materials 
3.1.1 General chemicals 
Table 3.1. General chemicals and compounds utilised in this thesis 
Name  Supplier Cat. No 
2-Mercaptoethanol Sigma-Aldrich  M3148 
Agarose Bio-Rad 161-3102 
Aluminium ammonium sulphate Sigma-Aldrich  202568 
Ammonium hydroxide Sigma-Aldrich  320145 
Boric acid Sigma-Aldrich  185094 
Bovine serum albumin Sigma-Aldrich  A9647 
Citric acid UNIVAR B/NO.1203045 
Dabrafenib CAYMAN CHEMICAL 1195765-45-7 
Ethanol POCD ETHABS5P 
Ethylenediaminetetraacetic acid Sigma-Aldrich  E6758 
Folic acid Sigma-Aldrich  F7876 
Formalin Sigma-Aldrich  HT501128 
Glacial Acetic Acid Sigma-Aldrich  PHR1748 
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Glycerol Sigma-Aldrich  G9012 
Glycine ANALAR NORMAPUR 10119CU 
Haematoxylin  Sigma-Aldrich  H9627 
Hydrogen peroxide UNIVAR B/NO.1611231569 
Methanol POCD METH5P 
Periodic acid POCD PERIO50%/100 
Schiff's reagent POCD SCHIFFS500ML 
Sodium chloride MERCK K40428104 939 
Sodium hydrogen carbonate ANALAR NORMAPUR 10247 
Sodium hydroxide UNIVAR B/NO.1301133957 
Sodium iodate Sigma-Aldrich  S4007 
Streptozotocin Sigma-Aldrich  S0130 
TRIS ASTRAL SCIENTIFIC 497 
TRIS hydrochloride Sigma-Aldrich  T3253 
Tween 20 Sigma-Aldrich  P1379 
Xylene POCD XYLENEPL5LT 
 
3.1.2 Buffers and solutions 
3.1.2.1 Buffers for genotyping 
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0.2M NaOH/ 1 mM Ethylenediaminetetraacetic acid (EDTA) solution 
 
Tris-HCl/Citric acid solution: 
0.33M Tris-HCl pH 8.5 
0.1M citric acid 
 
Tris-borate-EDTA (TBE) electrophoresis buffer (10X) 
1 M Tris base  
1 M Boric acid  
0.02 M EDTA  
 
3.1.2.2 Buffers for immunohistochemistry 
Heat retrieval solution, pH 6.0 
0.01M Citrate buffer 
 
Tris-buffered saline with Tween 20 (TBST) wash buffer, pH 7.6 
0.05M Tris 
0.15M NaCl 
0.05% Tween 20 
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Mayer’s Haematoxylin 
0.5% (w/v) Haematoxylin 
5% (w/v) Aluminium ammonium sulphate 
0.03% (w/v) Sodium iodate 
2% (v/v) Glacial acetic acid 
30% (v/v) Glycerol 
 
Scott's bluing solution 
0.5% (v/v) Ammonium hydroxide  
 
3.1.2.3 Buffers for western blot 
Lysis buffer 
1× Radioimmunoprecipitation assay (RIPA) buffer (Thermo Scientific) 
1× Protease and Phosphatase Inhibitor Cocktail, EDTA-free (Roche) 
 
Transfer buffer 
25mM Tris 
190mM Glycine 
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20% Methanol 
 
TBST buffer 
20mM Tris, pH7.5 
150mM NaCl 
0.1% Tween 20 
 
Blocking buffer 
5% BSA in TBST 
 
3.1.3 The sequence of probes and primers  
Table 3.2. The sequence of probes used for quantitative real-time PCR 
Target (Assay ID) Sequence (FAM labelled Probe/ Primer 2 /Primer 1 Sequence 5' -
-> 3') 
ASC 
Mm.PT.56a.42872867 
/56-FAM/CAG TGT CCC /ZEN/TGC TCA GAG TAC AGC /3IABkFQ/ 
GCT TAG AGA CAT GGG CTT ACA G 
GGT CCA CAA AGT GTC CTG TT 
F4/80 /56-FAM/AGT CTG GGA /ZEN/ATG GGA GCT AAG GTC 
A/3IABkFQ/ 
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Mm.PT.58.11087779 ATT CAC TGT CTG CTC AAC CG 
GGA AGT GGA TGG CAT AGA TGA 
hCollagen IV 
Hs.PT.58.15679435 
/56-FAM/TCA TAC AGA /ZEN/CTT GGC AGC GGC T/3IABkFQ/ 
AGA GAG GAG CGA GAT GTT CA 
TGA GTC AGG CTT CAT TAT GTT CT 
hFibronectin 
Hs.PT.58.40005963 
/56-FAM/TAC AGC TTA /ZEN/TTC TCC CTC GCC CAG /3IABkFQ/ 
CGT CCT AAA GAC TCC ATG ATC TG 
ACC AAT CTT GTA GGA CTG ACC 
hTGF-β1 
Hs.PT.58.39813975 
/56-FAM/ACC CGC GTG /ZEN/CTA ATG GTG GAA /3IABkFQ/ 
CCG ACT ACT ACG CCA AGG A 
GTT CAG GTA CCG CTT CTC G 
hTubulin 
Hs.PT.58.27209704 
/56-FAM/ACT CAC GCA /ZEN/TGG TTG CTG CTT C/3IABkFQ/ 
TCT CTT ACA TCG ACC GCC TA 
CAT TGC CAA TCT GGA CAC CA 
IL-1β 
Mm.PT.58.41616450 
/56-FAM/TTC CAA ACC /ZEN/TTT GAC CTG GGC TGT /3IABkFQ/ 
GAC CTG TTC TTT GAA GTT GAC G 
CTC TTG TTG ATG TGC TGC TG 
mCollagen IV /56-FAM/TCT TTC TCC /ZEN/CTT TTG TCC CTT CAC GC/3IABkFQ/ 
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Mm.PT.58.31838522 TCT GGC TGT GGA AAA TGT GA 
AAT CCA ATG ACA CCT TGC AAC 
MCP-1 
Hs.PT.58.45467977 
/56-FAM/TCA ATG CCC /ZEN/CAG TCA CCT GCT /3IABkFQ/ 
AGC AGC CAC CTT CAT TCC 
GCC TCT GCA CTG AGA TCT TC 
mFibronectin 
Mm.PT.58.8135568 
/56-FAM/CAG GAG ATT /ZEN/TGT TAG GAC CAC GGC 
A/3IABkFQ/ 
GAG CTA TCC ATT TCA CCT TCA GA 
TTG TTC GTA GAC ACT GGA GAC 
mGAPDH 
Mm.PT.39a.1 
/56-FAM/TGC AAA TGG /ZEN/CAG CCC TGG TG/3IABkFQ/ 
AAT GGT GAA GGT CGG TGT G 
GTG GAG TCA TAC TGG AAC ATG TAG 
mTGF-β1 
Mm.PT.58.11254750 
/56-FAM/ATA GAT GGC /ZEN/GTT GTT GCG GTC CA/3IABkFQ/ 
GCG GAC TAC TAT GCT AAA GAG G 
CCG AAT GTC TGA CGT ATT GAA GA 
mTubulin 
Mm.PT.58.13069923 
/56-FAM/CAT GTT CCA /ZEN/GGC AGT AGA GCT CCC /3IABkFQ/ 
CGC GAA GCA GCA ACC AT 
TCT TGT CAC TTG GCA TCT GG 
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NLRP3 
Mm.PT.58.13974318 
/56-FAM/TGC CTC ACT /ZEN/TCT AGC TTC TGC CG/3IABkFQ/ 
CAC TCA TGT TGC CTG TTC TTC 
CGG TTG GTG CTT AGA CTT GA 
RIPK3 
Mm.PT.58.12712973.g
s 
/56-FAM/TCC CAG GAT /ZEN/ATC TTC TTC GAG TTC ACG 
AT/3IABkFQ/ 
GGA ACC ATG ATG TAG CAG TCA 
CTC ATT ACG AAG ATT AAC CAT AGC C 
TLR2 
Mm.PT.58.45820113 
/56-FAM/CCA AAG AGC /ZEN/TCG TAG CAT CCT CTG A/3IABkFQ/ 
CAA CTT ACC GAA ACC TCA GAC A 
CCA GAA GCA TCA CAT GAC AGA 
TLR4 
Mm.PT.58.41643680 
/56-FAM/ACT CAG CAA /ZEN/AGT CCC TGA TGA CAT TCC 
/3IABkFQ/ 
GAA GCT TGA ATC CCT GCA TAG 
AGC TCA GAT CTA TGT TCT TGG TTG 
TNFα 
Mm.PT.58.12575861 
/56-FAM/CCA CGT CGT /ZEN/AGC AAA CCA CCA AGT /3IABkFQ/ 
AGA CCC TCA CAC TCA GAT CA 
TCT TTG AGA TCC ATG CCG TTG 
α-SMA 
Mm.PT.58.16320644 
/56-FAM/CCG CTG ACT /ZEN/CCA TCC CAA TGA AAG A/3IABkFQ/ 
GAG CTA CGA ACT GCC TGA C 
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CTG TTA TAG GTG GTT TCG TGG A 
 
Table 3.3. Primer sets used for genotyping 
 
Sequence 5' --> 3' 
eNOS primers AAT TCG CCA ATG ACA AGA CG 
AGG GGA ACA AGC CCA GTA GT 
CTT GTC CCC TAG GCA CCT CT  
RIPK3 primers CGC TTT AGA AGC CTT CAG GTT GAC 
GCC TGC CCA TCA GCA ACT C 
CCA GAG GCC ACT TGT GTA GCG 
 
3.2 Animal models 
All animals were housed in the Kearns Animal Facility of the Kolling Institute of Medical 
Research, with a stable environment maintained at 22 ± 1°C with a 12/12h light-dark cycle. 
Experiments were done in accordance with the National Health and Medical Research 
Council of Australia’s Code for the Care and Use of Animals for Scientific Purposes and were 
approved by the Animal Research Ethics Committee of the Royal North Shore Hospital 
(NSLHD reference RESP/15/206). 
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Wild-type (WT) mice were obtained from Kearns Animal Facility of the Kolling Institute of 
Medical Research, RIPK3-/- mice were a gift from Genetech, San Francisco, CA 94080; eNOS-
/- mice were purchased Jacksons Laboratory, USA. 7-9 weeks old male mice weighing 20-25g 
were used for this study. All mice had a C57BL/6 background. 
 
3.2.1 Genotyping of genetically modified mice 
Mouse genomic DNA was isolated from mouse tail tips (1-2 mm) by incubating tips with 
40μl 0.2M NaOH/ 1 mM EDTA solution and heated at 95°C for 10 minutes. After incubation, 
the tubes were vortexed for 2 minutes while still hot. 40μl of Tris-HCl/Citric acid solution 
was then added to each tube and further vortexed for 2 minutes. The tubes were then 
centrifuged for 2 minutes at 20200 rpm. 1μl solution from the tube was added to the 
HotFirePol master mix for the PCR. The final concentration of primers in the PCR reaction 
was 0.4μM (as showed in Table 3.4).  
 
Table 3.4 Protocol of genotyping  
Reagent For 1 reaction For 10 reactions 
5x HotFirePol 4 μl 40 μl 
Primers from 4μM stock 2 μl 20 μl 
water 13 μl  130 μl 
Add DNA (1μl/tube)   
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PCR conditions were as follows: 
95°C - 8 minutes 
95°C – 30 seconds 
60°C – 30 seconds (for mRIP3= 60°C, for eNOS=65°C) 
72°C – 60 seconds 
42 cycles 
 
PCR products were measured with 2% agarose DNA electrophoresis. Agarose gels were 
prepared at 2% (w/v) using TBE buffer, with SafeView DNA Stains (abm) being added to the 
molten agarose, to allow for visualisation of DNA bands under UV light, and allowed to cool 
before PCR samples were loaded into the gel. Electrophoresis was run at 100-120V for 45-60 
min, or until the dye reached the end of the gel. DNA bands were visualised under UV light 
and recorded using the BioRad Chemidoc system. 
 
3.2.2 Establishment of diabetic mice 
Mice were fasted for 4 hours and then received either 55 mg/kg STZ diluted in 0.1 M citrate 
buffer, pH 4.5, or citrate buffer alone by intraperitoneal injection for five consecutive days. 
Animals serving as non-diabetic controls were injected with citrate buffer alone. Blood 
glucose levels were monitored weekly to confirm the diabetic status of these mice. Only 
STZ-treated animals with blood glucose >16 mmol/L were considered diabetic for the 
purpose of inclusion in subsequent studies as detailed in this thesis.  
62 
 
 
Post STZ induction and experimental procedures, blood glucose monitoring was done twice 
a week until diabetes was established, then it was done weekly. To do so, the tip of the tail 
was wiped with 70% ethanol prior to blood collection and a blood sample (approximately 
5µl) was obtained via tail vein prick near the tip of the tail using a sterile scalpel blade, and 
blood glucose was measured using a Nano Accu-Chek Blood Glucose Monitor. Insulin 
(Lantus 2U/ day) was given subcutaneously if glucose exceeded 28 mmol or if they showed 
significant weight loss after induction of diabetes (10-15% body weight loss of mouse with 
blood glucose >16 mmol/L). For animals that required insulin, blood sugar measurement 
was performed twice a week. Mice were monitored by clinical observation for signs of 
dehydration and signs of distress (e.g. inactive, matted hair, etc). Weight was measured 
every week to ensure animal wellbeing. Urine collection from the metabolic cage was 
performed at week 24 after the last STZ injection.  
 
3.2.3 Establishment of FA-induced nephropathy 
Mice were fasted for 4 hours and the folic acid was administrated to mice by intraperitoneal 
injection (i.p.) at a dose of 250 mg/kg in the vehicle (0.5 ml of 0.3 M NaHCO3) to induce 
nephropathy. After injection, mice were carefully observed for any sign of distress and 
lesions at injection site. A 28-day model was used in our study. Hence animals were culled at 
week 4 after folic acid administration. Mice were also carefully observed for general well-
being throughout the duration of the experiments.  
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3.2.4 Implantation of osmotic minipumps  
Osmotic minipumps were implanted in the interscapular region subcutaneously under short 
inhalational anaesthesia with 2% isoflurane, nitrous oxide (2L/minute) and oxygen (1L/min). 
The anaesthetised mice were immobilised on a surgical pad. A mid-scapular incision was 
made on the back of the animal. By inserting a haemostat into the incision, and opening and 
closing the jaws of the haemostat, a pocket for the pump was created by spreading the 
subcutaneous tissue, which was used to insert the filled pump. The wound was sutured 
using surgical silk. The mice were recovered on a heating pad and once recovered, they 
were moved to their original cages. Mice were given an analgesic drug (Buprenorphine, 
Temgesic 0.03mg/kg IP) for pain induced by surgery immediately before the procedure and 
4 hours after the procedure. Potential infection at the incision point, and the wellbeing of 
mice were observed closely daily. For the diabetic kidney disease model, the osmotic 
minipumps were replaced every 6 weeks, while implantation surgery was done only once on 
folic acid mice model (implantation of minipump was performed as described in methods of 
chapter 4 and 5). 
 
3.2.5 Euthanasia of animals and tissue collection 
At the designated experimental endpoint, mice were humanely euthanised and sacrificed 
under anaesthetic by 2% Isoflurane, nitrous oxide (2L/min) and oxygen (1L/min). 
Thoracotomy was performed when the animal was fully anaesthetised and then tissues 
were harvested. The kidney, in particular, was sliced longitudinally, with one half being 
fixated in 10% neutral-buffered formalin for histological analysis, while the other half was 
snap-frozen in liquid nitrogen and stored at -80°C.  
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3.2.6 Tissue embedding and fixation 
Tissue samples for fixing were immediately placed in cassettes and placed in formalin for 12-
24 hours depending on the size of the tissue, then dehydrated in ethanol (70%, 95% then 
100%) and processed using a tissue embedding processor (Excelsior ES, Thermo Scientific). 
The samples were then embedded in paraffin using a paraffin dispenser before sectioning. 
The kidneys were sectioned at the thickness of 4 µM. 
 
3.3 Histology 
3.3.1 PAS staining 
After being deparaffinised using xylene and hydrated in distilled water, slides were 
immersed in 1% periodic acid solution for 15 minutes at room temperature. The slides were 
washed and immersed in Schiff’s solution for 15 minutes. Once washed, slides were 
incubated in Mayer’s Haematoxylin for 3 minutes and washed in running water for 3 
minutes, followed by incubation in Scott’s bluing solution for 1 minute to stain the nuclear. 
Then slides were washed, dehydrated and mounted (HEUCKITT, ThermoFisher). 
 
3.3.2 Picrosirius Red stain 
According to manufacturer’s instructions (Picrosirius Red Stain Kit, 24901-500, 
Polysciences), paraffin sections on slides were firstly deparaffinized and hydrated in distilled 
water and then placed in phosphomolybdic acid (solution A) for 2 minutes. Once washed, 
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slides were incubated in Picrosirius Red F3BA Stain (solution B) for 60 minutes, followed by 
incubation in 0.1N Hydrochloride Acid solution (solution C) for 2 minutes. After staining, 
slides were placed in 70% ethanol for 45 seconds dehydrated and mounted.  
 
3.4 Immunohistochemistry 
Deparaffinisation and hydration of slides are as described above. Heat retrieval was 
processed using a boiling water bath. The slides were heated in hot retrieval buffer at 99 ℃ 
for 20 minutes and cooled for another 20 minutes at room temperature within the hot 
retrieval buffer. Slides were then washed in running tap water for 3 minutes and immersed 
in 0.3% H2O2 for 5 minutes. Once washed, slides were ready for antibody incubation using 
Sequenza system (Thermo Scientific Shandon Coverplate Technology). Firstly, blocking 
buffer (Protein Block, Serum-Free, Dako X0909) was used and slides were blocked for 10 
minutes. The diluted primary antibody (Antibody Diluent, Dako S0809) was added to each 
chamber along with the negative control (mouse negative control Dako X0931, rabbit 
negative control Dako X0930) and incubated at 4℃ overnight. The next day, the secondary 
antibody (EnVision + Rabbit Dako K4003, EnVision + Mouse Dako K4001) was added to slides 
after washing with TBST and incubation for 30 minutes. After washing, slides were 
incubated with substrate chromogen to cover the kidney sections (DAB+ Peroxidase 
Substrate Dako K3468) for 10 minutes at room temperature. The reaction was stopped and 
slides washed in running tap water, nuclear staining, dehydration and mounting were 
processed as previously described.  
 
66 
 
3.5 mRNA expression by RT-PCR analysis 
3.5.1 RNA extraction  
RNA was extracted from cells using the isolate RNA kit (Isolate II RNA Mini Kit, BIO-52073, 
Bioline). Cell lysis was generated by adding lysis butter and β-ME to the cell pellet or to the 
ground tissue and vortexed vigorously. The lysate was filtered with the supplied collection 
tubes and mixed with 70% ethanol to adjust the RNA binding conditions. After binding RNA 
to the silica membrane of the RNA minicolumns, membrane desalting buffer was added to 
dry the membrane and DNase was added to digest DNA. Once the membrane was washed 
and dried, RNA was eluted with RNase-free water and measured by Nano-drop (ND-1000 
Spectrophotometer, ThermoFisher Scientific). 
 
Total RNA was extracted from mouse kidney cortex tissues using the RNeasy plus mini kit 
(Qiagen) by QIAcube (Qiagen). The obtained RNA was eluted with RNase-free water and 
measured with Nano-drop (ND-1000 Spectrophotometer, ThermoFisher Scientific). 
 
3.5.2 cDNA synthesis 
iScript cDNA Synthesis Kit (1708891, BioRad) was used in our study. As per the 
manufacturer’s instructions, 1µg total RNA from each sample was used as the RNA 
template. The reaction was undertaken as per the following tables (Table 3.5 and 3.6).  
 
Table 3.5 Components of cDNA synthesis 
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Components  Volume per reaction (µl) 
5×iScript Reaction Mix 4 
iScript Reverse Transcriptase 1 
Nuclease-free water + RNA template (1µg) 15 
Total volume 20 
 
 
Table 3.6 Reaction Protocol of cDNA synthesis 
Priming 5 minutes at 25 ℃ 
Reverse transcription 20 minutes at 46℃ 
RT inactivation 1 minute at 95℃ 
Holding step 4℃ 
 
3.5.3 PCR 
Quantitative real-time PCR was performed using the master mix (BIO-82005, Bioline) with 
the probes as shown in Table 3.2 on the ABIPrism-7900 Sequence Detection System (Applied 
Biosystems). The reaction was per the following table (Table 3.7). The relative mRNA 
expression levels were calculated according to the 2_∆∆Ct method using Expression Suite 
software (ThermoFisher Scientific). 
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Table 3.7 Reaction Protocol of PCR 
Polymerase activation 2 minutes at 95 ℃ 
Denaturation 10 seconds at 95℃ 
40 cycles 
Annealing/extension 1 minute at 60℃ 
 
3.6 Western blot analysis 
3.6.1 Protein extraction  
For protein extraction, the supernatant of cell culture medium was collected and stored at -
80℃. Cell culture dishes or plates were placed on ice and washed with ice-cold TBS. After 
aspiration of TBS, ice-cold RIPA buffer was added to the dish or plate and a cold plastic cell 
scraper was used to scrape adherent cells off the dish/plate and then the cell suspension 
was transferred into a precooled microcentrifuge tube and maintained with constant 
agitation for 30 minutes at 4 ℃.  The tube was spun at 16,000×g for 20 minutes in a 4℃-
precooled centrifuge and the supernatant was kept at -20℃ and the pellet discarded.  
Protein extraction from tissue was similar. After the kidney was cut, TissueRuptor II 
(QIAGEN) was used to homogenize the tissue together with the RIPA buffer. The lysate was 
centrifuged, and the supernatant collected and stored at -20℃. 
 
3.6.2 Bicinchoninic acid (BCA) protein assay  
The protein concentration was quantified using the Pierce BCA Protein Assay Kit (Thermo 
Scientific). According to the manufacturer’s instructions, samples were applied in duplicate 
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to the plate, along with a reference BSA standard dilution series, and incubated for 30 
minutes at 37℃. The absorbance at 560nm was determined using a microplate reader. 
Using the microplate reader software, a standard curve was produced to calculate the 
protein concentration of each sample. 
 
3.6.3 Protein gel electrophoresis 
Samples were mixed with the sample buffer and the reducing buffer (Novex Bolt TM, 
Invitrogen) and heated at 70°C for 10 minutes followed by 5 minutes cooling to 4 °C. 
Approximately 20 μg/lane of the sample was loaded into Bolt 4-12% Bis-Tris Plus Gels 
(Thermo Fisher Scientific). The gel was run at 165 V for 1.5 hr or until the dye front reached 
the end of the gel (BlotTM MES SDS Running buffer, Invitrogen). Electrophoresed proteins 
were then transferred from the gel onto nitrocellulose membranes (A10235589, Amersham) 
using the Wet/Tank Blotting System (Bio-Rad). Membranes were blocked with 5% (w/v) BSA 
in TBST for 1 hour at room temperature, before being incubated with the primary antibody 
overnight at 4 °C. After several washes with TBST, membranes were probed with an 
appropriate secondary antibody for 1 hour at room temperature. The membranes were 
then detected using ECL (Immobilon Crescendo Western HRP substrate, Millipore) with LAS-
4000 Imaging System (Fujifilm). Gel-pro software was used to analyse the densitometry of 
immunoblot images. 
 
3.7 In vitro studies  
3.7.1 HK2 cell culture 
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HK2 cells (human renal proximal tubular epithelial cells immortalized by transduction with 
human papilloma virus16 E6/E7 genes) purchased from ATCC were grown in keratinocyte 
serum-free media medium (Invitrogen, CA). Cells were grown at 37°C in 5% CO2 and 95% air. 
Fresh growth medium was added to cells every other day until confluent. The cells used in 
this experiment were at passages 10-15. 
 
3.7.2 Cell proliferation assay 
Cell proliferation assays were measured with Cell Proliferation Assay kit (TB245, Promega). 
20 µl of reagent was added into each well of the 96-well plate containing the samples in 
100µl of culture medium. The plate was incubated at 37°C for 4 hours in a humidified, 5% 
CO2 atmosphere and absorbance was recorded at 490nm using a plate reader. 
 
3.8 Statistics 
Unless otherwise stated all data are presented as mean ± S.E.M. The differences between 
two groups were analysed by the two-tailed t-test, and Comparison of multiple groups was 
analysed by one-way analysis of variance ANOVA followed by Tukey's multiple comparisons 
test. A two-sided p-value < 0.05 was considered statistically significant. 
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Chapter 4 RIPK3 blockade attenuates kidney fibrosis in a 
folic acid model of renal injury 
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Abstract 
Renal fibrosis is common to all forms of progressive kidney disease. However, current 
therapies to limit renal fibrosis are largely ineffective. Phosphorylation of receptor-interacting 
serine/threonine-protein kinase (RIPK) 3 has been recently suggested to be a key regulator of 
the pyrin domain containing 3 (NLRP3) inflammasome and the common pathway of toll-like 
receptor (TLR) 2 and 4, which provides new insights into mechanisms of chronic kidney 
disease (CKD).   However, the specific effect of RIPK3 on renal cortical fibrosis has not been 
fully understood. To study the function of RIPK3, both genetic ablation and pharmacological 
inhibition of RIPK3 (dabrafenib) were used in the study. Our studies identify that RIPK3 
promotes renal fibrosis via the common pathways of activation of TLR2 and 4 and the NLRP3 
inflammasome in a mouse model of folic acid-induced nephropathy. Both interventional 
strategies decreased the renal fibrotic response. In dissecting the relevant pathways, 
differential inhibition was observed in the transforming growth factor beta (TGF-β) 1 and 
mitogen-activated protein kinase (MAPK) pathways, but beneficial effects converged on the 
TLR2/4 and NLRP3 pathways. This study demonstrates a role for RIPK3 as the mediator of 
renal fibrosis via upregulation of TLR2/4 pathways and inflammasome activation. Dabrafenib, 
as an inhibitor of RIPK3, may be an effective treatment to limit the progression of the 
tubulointerstitial fibrosis. 
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4.1 Introduction  
Chronic kidney disease (CKD) is a worldwide public health issue. Regardless of the cause of 
initial renal injury, CKD leads to renal fibrosis, characterized by renal dysfunction, extracellular 
matrix (ECM) accumulation, myofibroblast activation and inflammatory responses [3, 4]. To 
date, the most widely used strategy to limit the progression of CKD is blockade of the renin-
angiotensin system, an approach that was developed more than 20 years ago with 
subsequently little therapeutic progress [332]. Therefore, identifying a novel therapeutic 
target to limit renal fibrogenesis is crucial to improve the outcomes of patients with CKD. 
 
As a key kinase in inducing cell death, receptor-interacting protein kinase (RIPK) 3 has been 
increasingly reported to promote inflammatory responses and tissue damage [25]. However, 
the role of RIPK3 on renal tubules in renal cortical fibrosis has not been elucidated. Our pilot 
studies on human kidney biopsies from patients with diabetic nephropathy demonstrated a 
higher RIPK3 protein expression in proximal tubules, suggesting a possible functional role for 
RIPK3 in tubular epithelial cells subjected to injury resulting in progressive renal fibrosis.  
 
Recent studies have identified that RIPK3 is an important mediator in the pyrin domain 
containing 3 (NLRP3) inflammasome formation [23]. It is well documented that elevation of 
RIPK3 activity induces an increase of phosphorylation of mixed-lineage kinase domain-like 
protein (MLKL) activity [25, 311], which leads to the NLRP3 activation [26]. Additionally, 
increased RIPK3 expression can directly promote expression of the NLRP3 inflammasome and 
associated inflammatory responses independent of MLKL [23-27, 318]. Furthermore, RIPK3 has 
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been demonstrated to promote cell-death-independent inflammation through toll like 
receptor (TLR) 4 activation in macrophages [28], indicating that RIPK3 is a crucial mediator of 
the TLR4 pathway. Importantly, it is well documented that activation of both NLRP3 and the 
TLR4 pathway contribute to tubulointerstitial fibrosis in diverse rodent models of kidney 
disease, such as unilateral ureteral obstruction and diabetic nephropathy [232, 258, 333-340]. 
Together, these studies indicate that RIPK3 may promote renal fibrosis through activation of 
the NLRP3 inflammasome and the TLR4 pathway. 
 
Dabrafenib is a well-known inhibitor of B-Raf, which suppresses the downstream 
Ras/Raf/extracellular-signal-regulated kinase (ERK)/ mitogen-activated protein kinase (MAPK) 
pathway [328] which has been approval for clinical use for the treatment of melanoma and 
non-small cell lung cancer expressing B-Raf V600E mutations [329]. Inhibition of Raf kinase is 
known to attenuate renal fibrosis in a rat model of autosomal dominant polycystic kidney 
disease (ADPKD) [330].  It is also recognised that transforming growth factor beta (TGF-β) 1 
can induce Ras/Raf/ERK/MAPK pathways [331], resulting in renal fibrosis. These studies 
indicate a potential renoprotective role of dabrafenib. Importantly, previous studies reported 
that dabrafenib is also a RIPK3 inhibitor which have been demonstrated in various models 
including human hepatocytes [326], mouse models of acetaminophen-induced liver injury 
[326] and ischemic brain injury [327]. Therefore, although GSK’872 is a more selective RIPK3- 
inhibitor [322], dabrafenib may have several mechanisms of benefit in the context of renal 
fibrosis. 
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Folic acid (FA) nephropathy is a widely used animal model to study interstitial fibrosis. FA 
causes renal injury as it is directly toxic to tubular epithelial cells. Hence it is a useful model 
to study tubular injury and subsequent renal pathology. FA initiates tubular dysfunction in the 
acute phase (1-14 days) and interstitial fibrosis in chronic phase (28-42 days) [253], thus a 28-
day FA nephropathy model of tubulointerstitial fibrosis was used in this study. 
 
In the present study, we aimed to test the hypothesis that RIPK3 inhibition limits FA induced 
renal fibrosis. By developing the model in RIPK3 deficient mice and in wild-type mice treated 
with dabrafenib we were able to dissect the downstream pathways responsible for renal 
fibrosis.  
 
4.2 Methods 
4.2.1 Animal study  
RIPK3-/- mice were a kind gift from K. N [341]. Male RIPK3-/-(c57BL/6), RIPK3+/+ (c57BL/6) mice 
of 7-9 weeks old with weighing 20-25g were studied. All animals were housed in the Kearns 
Animal Facility of the Kolling Institute of Medical Research, with a stable environment 
maintained at 22 ± 1°C with a 2/12h light-dark cycle. FA nephropathy model was induced by 
a single intraperitoneal injection of FA (250 mg/kg in the vehicle of 0.3 M NaHCO3, pH 7.4). 
Control mice were injected with vehicle.  
 
Dabrafenib was used as the RIPK3 inhibitor in our study. Given that dabrafenib has very 
different oral bioavailability in humans (t1/2 4.8 hours for oral administration) [342, 343] 
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compared to mice (t1/2 23.7 min for oral administration) [344], Alzet model 2006 osmotic 
pumps (0.15 μl/hr, 42-day-pump model) were used to deliver dabrafenib. Before implantation 
surgery, pumps were incubated in sterile saline at 37 ℃ for 60 hours. Dabrafenib was 
dissolved in DMSO at a concentration of 16.7 mg/ml [344, 345]. Dabrafenib solution was 
delivered at a rate of 2.5 μg/hr. 24 hours following the FA injection, osmotic pumps were 
implanted on the back of mice to deliver dabrafenib or its vehicle DMSO. Mice were sacrificed 
28 days after the surgery [253].  
 
Experiments were done in accordance with the National Health and Medical Research Council 
of Australia’s Code for the Care and Use of Animals for Scientific Purposes and were approved 
by the Animal Research Ethics Committee of the Royal North Shore Hospital (NSLHD reference 
RESP/15/206). 
 
4.2.2 Histology and Immunohistochemistry 
Kidneys were fixed in 4% paraformaldehyde and embedded with paraffin. 4 μm kidney 
sections were cut and stained as follows. After deparaffinisation with xylene, slides were 
immersed in decreasing concentration of ethanol (100%, 100%, 95%, 70%) and rinsed in a 
container of running water. 1% periodic acid solution (PER50%/100, POCD Scientific) and 
Schiff’s reagent (SCH500, POCD Scientific) was used for Periodic Acid-Schiff (PAS) staining. 
Picrosirius Red stain (24901, Polysciences) was undertaken according to the manufacturer's 
protocol. 
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Citrate buffer in pH 6 was heated to 99 ℃ for epitope retrieval. Slides were placed in hot 
retrieval buffer for 20 minutes’ incubation followed by 20 minutes’ cooling to room 
temperature. Slides were blocked for 15 minutes (protein block serum-free ready to use 
x0909, Dako). Immunohistochemical staining was processed in Thermo Scientific Sequenza 
system. Slides were incubated overnight at 4℃ with primary antibodies against type I collagen 
(Abcam, ab34710, 1:750), a-SMA (Sigma-Aldrich, A2547, 1:2000), phospho-Smad2/3 (Santa 
Cruz, sc-11769, 1:75). Slides were then washed with TBS-T (50mM Tris, 150mM NaCl, 0.05% 
Tween 20, pH 7.6), and then incubated with associated secondary antibodies 
(EnVision+system-HRP labelled polymer anti-rabbit k4003, EnVision+system-HRP labelled 
polymer anti-mouse k4001, Dako) for 30 minutes at room temperature. After washing with 
TBS-T, kidney sections were covered with the DAB (liquid DAB+substrate chromogen system 
k3468, Dako) for 10 minutes. All experiments included controls without primary antibody. 
Staining was scored by multiplying the percentage of positive signals by the intensity. Score 
of intensity was from 1 to 5. Positive signals in the renal cortex regions were identified and 
quantified using Image J software. 
 
4.2.3 Renal cortical injury  
Renal cortical injury was blindly assessed in PAS-stained kidney sections. Abnormal cortical 
tissues containing tubular dilation, atrophy, cast formation or inflammatory cell infiltration 
were considered as being indicative of interstitial fibrosis/ tubular atrophy [55, 320]. 
Abnormal cortical area was identified and marked and then expressed as a percentage 
compared to the total cortical area using Photoshop software.  
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4.2.4 RNA isolation and RT-PCR analysis 
Total RNA was extracted from mouse kidney cortex tissues using RNeasy plus mini kit (Qiagen) 
by QIAcube (Qiagen). The cDNA was synthesized with a cDNA synthesis kit (Roche). 
Predesigned probes (PrimeTime® Assay Std Probe 5' 6-FAM™/ZEN™/3' IB®FQ, Integrated DNA 
Technologies), including RIPK3 (Assay ID: Mm.PT.58.12712973.gs), α-SMA (Assay ID: 
Mm.PT.58.16320644), TLR4 (Assay ID: Mm.PT.58.41643680), TLR2 (Assay ID: 
Mm.PT.58.45820113), NLRP3 (Assay ID: Mm.PT.58.13974318), ASC (Assay ID: 
Mm.PT.56a.42872867),  IL-1β (Assay ID: Mm.PT.58.41616450), TNF a (Assay ID: 
Mm.PT.58.12575861), TGF-β1 (Assay ID: Mm.PT.58.11254750), MCP-1 (Assay ID: 
Mm.PT.58.42151692), F4/80 (Assay ID: Mm.PT.58.11087779), Glyceraldehyde-3-Phosphate 
dehydrogenase  (GAPDH) (Assay ID: Mm.PT.39a.1) were used. Quantitative real-time PCR was 
performed using the Bioline SensiFast Probe Hi-Rox kit (BIO-82020) with probes on the ABI-
Prism-7900 Sequence Detection System (Applied Biosystems). The PCR reactions were run for 
40 cycles. Each amplification cycle included denaturation at 95℃ for 10 seconds and 
annealing/extension at 60℃ for 50 seconds. All reactions were done in duplicate. The relative 
mRNA expression level was calculated by ExpressionSuite software and GAPDH was used as 
an endogenous reference gene.  
 
4.2.5 Western blot analysis 
Mouse kidney cortex tissues were homogenized and lysed in RIPA buffer with protease 
inhibitors (Thermofisher). Tissue lysates were separated on 4-12% gels (Invitrogen) and then 
transferred to PVDF membrane (PALL) for 2 hours at 4 ℃. Membranes were blocked with 5% 
BSA in TBS-T (20 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.6) for 1 hour and then incubated 
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with primary antibodies (GAPDH, ab8245, Abcam; phospho-p65, sc-101749, Santa Cruz; p65, 
sc-372, Santa Cruz; phospho-ERK1/2, 9101s, Cell Signalling; ERK1/2, 4695s, Cell Signalling; 
MLKL, #37705, Cell Signalling; phospho-MLKL, #62233, Cell Signalling) at 4 ℃ overnight 
followed by relevant horseradish peroxidase-conjugated secondary antibody (anti-Rabbit 
antibody, Cell Signalling; anti-Mouse antibody, Santa Cruz). The membranes were then 
detected using ECL (Millipore) with LAS-4000 Imaging System (Fujifilm). Gel-pro software was 
used to analyse the densitometry of immunoblot images. 
 
4.2.6 Statistical analysis 
The results are presented as mean ± S.E.M. All statistical analyses were performed with 
GraphPad software. Statistical analysis of two groups was performed with the two-tailed t-
test. Comparison of multiple groups was analysed by one-way analysis of variance ANOVA 
followed by Tukey's multiple comparisons test. A two-sided p-value < 0.05 was considered 
statistically significant. 
 
4.3 Results  
4.3.1 RIPK3 gene expression is increased in mice with FA nephropathy but no change 
observed in downstream pMLKL protein 
RIPK3 mRNA expression in the kidney was significantly increased in wild-type mice with FA 
nephropathy compared with control mice (Fig 4.1a P<0.0001). Despite the upregulation of 
RIPK3, FA nephropathy did not induce a significant downstream effect on phosphorylated 
MLKL protein, suggesting renal injury and the subsequent fibrotic response is independent of 
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MLKL induced necroinflammation (Fig. 4.1 b, c). As expected, no mRNA expression of RIPK3 
was found in RIPK3-/- mice.  
 
 
 
Figure 4.1 Increased receptor-interacting serine/threonine-protein kinase (RIPK) 3 in mice 
with folic acid nephropathy. (a) mRNA expression of RIPK3 was measured with q-PCR in mice 
(wild-type vs RIPK3-/-) with/without folic acid nephropathy. Glyceraldehyde-3-Phosphate 
dehydrogenase (GAPDH) was used as the reference gene. Statistical analysis of RIPK3 mRNA 
expression was performed using the two-tailed t-test (t=5.304; df=20). ****, P < 0.0001. n = 
10-12 animals per group.  (b, c) Immunoblot analyses of kidneys from the same groups as in 
(a) using antibodies for phospho-mixed-lineage kinase domain-like (MLKL), total MLKL and 
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GAPDH as loading control. Statistical analysis was performed using one-way ANOVA followed 
by Tukey's multiple comparisons test. Results are presented as mean ± S.E.M. n = 4 animals 
per group. 
 
4.3.2 RIPK3 deficiency inhibits TLR2/4 signalling in mice with FA nephropathy.  
To determine whether RIPK3 mediated TLR2/4 signalling is elevated in FA-induced renal 
fibrosis, we compared wild-type and RIPK3 -/- mice, with or without FA-induced nephropathy. 
RT-PCR was performed to quantify TLR2 and TLR4 mRNA expression. Both TLR2 and TLR4 
mRNA expression levels were significantly upregulated in wild-type FA nephropathy mice 
compared to control mice (P<0.0001, Fig. 4.2 a, b). RIPK3 deletion significantly reduced the 
TLR2 and TLR4 mRNA expression (all P<0.05, Fig. 4.2 a, b). We then measured downstream 
markers of TLR2/4 common signalling, including nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB) signalling pathways and proinflammatory cytokines interleukin-1 (IL-
1) β and tumor necrosis factor (TNF) α. Phosphorylated p65 protein level was assessed as a 
downstream marker of the NFκB signalling pathway. FA nephropathy was associated with 
significantly elevated mRNA expression levels of IL-1β and TNF α (both P<0.05, Fig. 4.2 c, d). 
However, there were no significant differences in phosphorylated p65 levels in the kidneys 
between these groups. Deletion of RIPK3 decreased mRNA expression of IL-1β and TNF α (Fig. 
4.2 c, d). These results indicate that ablation of RIPK3 suppresses FA-induced TLR2/4 pathway 
activation with associated reduction in downstream IL-1β and TNF α.  
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Figure 4.2 Increased toll-like receptor (TLR) 2/4 in mice with folic acid nephropathy. (a-d) 
mRNA expression of TLR2, TLR4, interleukin (IL) -1β, tumour necrosis factor-α (TNFα), were 
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measured with q-PCR in mice (wild-type vs RIPK3-/-) with/without folic acid nephropathy. 
GAPDH was used as the reference gene. Statistical analysis was performed using one-way 
ANOVA followed by Tukey's multiple comparisons test. Results are presented as mean ± S.E.M. 
*, P < 0.05. ***, P < 0.001. ****, P < 0.0001. n = 10-12 animals per group.  (e, f) Immunoblot 
analyses of kidneys from the same groups as in (a) using antibodies for phospho-p65, total 
p65 and GAPDH as loading control. Statistical analysis was performed using one-way ANOVA 
followed by Tukey's multiple comparisons test. Results are presented as mean ± S.E.M. n = 4 
animals per group. 
 
4.3.3 RIPK3 deficiency reduces NLRP3 inflammasome activation in mice with FA 
nephropathy.  
To assess whether RIPK3 mediated NLRP3 activation is increased in FA-induced nephropathy, 
the inflammasome components were determined by RT-PCR. FA-induced nephropathy 
significantly elevated the mRNA expression levels of NLRP3 and adapter protein apoptosis-
associated speck-like protein (ASC), which is known to facilitate recruitment of inflammasome 
complex [191] (P<0.0001, Fig. 4.3 a, b). These effects were down-regulated in RIPK3-/- mice 
exposed to FA (Fig. 4.3a, b). These data demonstrate that RIPK3 deletion inhibits NLRP3 
activation in the context of a FA nephropathy model. 
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Figure 4.3 Increased pyrin domain-containing protein 3 (NLRP3) inflammasome activation 
in mice with folic acid nephropathy. (a, b) mRNA expression of NLRP3, adapter protein 
apoptosis-associated speck-like protein (ASC) were measured with q-PCR in mice (wild-type 
vs RIPK3-/-) with/without folic acid nephropathy. GAPDH was used as the reference gene. 
Statistical analysis was performed using one-way ANOVA followed by Tukey's multiple 
comparisons test. Results are presented as mean ± S.E.M. *, P < 0.05. ****, P < 0.0001. n = 
10-12 animals per group. 
 
4.3.4 RIPK3 deficiency reduces inflammatory responses and renal injury in mice with FA 
nephropathy.  
Monocyte chemoattractant protein (MCP)-1 and the marker of macrophage infiltration F4/80 
are well-recognized components of the inflammatory response, which can be regulated by 
multiple signalling pathways including NF κB [346], MAPK [347] and AKT [348]. To investigate 
whether RIPK3 deletion reduces FA-induced inflammatory responses and associated renal 
injury, RT-PCR was undertaken to assess MCP-1 and F4/80 mRNA expression levels within 
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kidneys of control and FA models in wild-type and RIPK3 -/- mice. As shown in Fig. 4.4 a, MCP-
1 mRNA expression was significantly increased in wild-type mice with FA nephropathy versus 
control (P<0.0001, Fig. 4.4 a). In contrast, RIPK3-/-mice with FA nephropathy exhibited lower 
MCP-1 gene expression than their wild-type counterparts (P<0.001, Fig. 4.4 a). In addition, we 
observed wild-type mice with FA nephropathy had significantly higher mRNA expression of 
F4/80 compared to control (P<0.0001, Fig. 4.4 b). In RIPK3-/- mice this increase was largely 
abrogated (P<0.01, Fig. 4.4 b). Together, these data suggest that the absence of RIPK3 
attenuates FA-induced inflammatory responses within the kidney. 
 
Blinded assessment of renal cortical injury consistently demonstrated increased renal injury 
within the kidney cortex in the FA-exposed wild-type animals, characterized by tubular 
dilation, tubule atrophy, cast formation or inflammatory cell infiltration (P<0.0001, Fig. 4.4 c, 
d). RIPK3 deletion was associated with less histological evidence of renal cortical injury 
(P<0.01, Fig. 4.4 c, d).  
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Figure 4.4 Increased inflammation and kidney injury in mice with folic acid nephropathy. (a, 
b) mRNA expressions of monocyte chemoattractant protein (MCP-1) and F4/80 were 
measured with q-PCR in mice (wild-type vs RIPK3-/-) with/without folic acid nephropathy. 
GAPDH was used as the reference gene. (c) Representative images of Periodic Acid-Schiff 
(PAS)-stained kidney sections. Magnification: 1× (left column); 20× (right column). (d) 
87 
 
Quantitation of renal cortical injury in the same groups as in (a). Statistical analysis was 
performed using one-way ANOVA followed by Tukey's multiple comparisons test. Results are 
presented as mean ± S.E.M. **, P < 0.01. ***, P < 0.001. ****, P < 0.0001. n = 10-12 animals 
per group. 
 
4.3.5 RIPK3 deficiency decreases TGF-β1 signalling and myofibroblast activation in mice 
with FA nephropathy.  
To investigate the association between RIPK3 and TGF-β1 in renal fibrogenesis, components 
of the TGF-β1 signalling pathway were determined using RT-PCR and immunohistochemistry. 
FA resulted in significant up-regulation of TGF-β1 mRNA expression, which was reduced by 
RIPK3 deletion (all P<0.05, Fig. 4.5 a). It is well documented that Smad 2/3 and ERK1/2 are 
crucial downstream proteins of TGF-β1 fibrogenic signalling. As shown in Fig. 4.5 b and c, FA-
induced nephropathy resulted in a significant elevation of p-Smad2/3 protein expression 
within the kidney cortex (P<0.01), whereas this effect was reversed in RIPK3-/- mice exposed 
to FA (P<0.001). In addition, FA nephropathy was associated with a significant increase in 
phosphorylated ERK1/2 (P<0.05, Fig. 4.5 d, e), which was partially reduced by RIPK3 deletion 
(P=0.0585, Fig. 4.5 d, e).  
 
It is well known that myofibroblast activation is a dominant feature of renal fibrosis. To assess 
if RIPK3 contributes to myofibroblast activation, α-smooth muscle actin (α-SMA) was 
measured. As shown in Fig. 4.5 f, α-SMA mRNA expression was significantly higher in wild-
type mice with FA nephropathy compared to control mice (P<0.0001), which was significantly 
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decreased in RIPK3 deficient mice (P<0.0001). To ascertain myofibroblast activation in the 
kidney cortex, α-SMA protein expression was evaluated by immunohistochemistry. α-SMA 
protein expression was consistently upregulated in FA-induced nephropathy compared to 
control kidneys (P<0.0001, Fig. 4.5 g, h), which was reversed in RIPK3-/- mice (P<0.0001, Fig. 
4.5 g, h). These data demonstrate that RIPK3 gene deletion results in suppressed TGF-β1 
signalling and myofibroblast activation within the kidney cortex in the FA nephropathy model. 
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Figure 4.5 Increased transforming growth factor beta (TGF-β) 1 signalling and myofibroblast 
activation in mice with folic acid nephropathy. (a, f) mRNA expression of α-smooth muscle 
actin (α-SMA) and TGF-β1 were measured with q-PCR in mice (wild-type vs RIPK3-/-) 
with/without folic acid nephropathy. GAPDH was used as reference gene. (b, g) 
Representative images of p-Smad2/3 and α-SMA stained kidney sections from the same 
groups as in (a). Scale bar: 200 μm. Magnification: 10× (left column); 40× (right column). (c, h) 
Quantitation of p-Smad2/3 and α-SMA immunohistochemical staining in the same groups as 
in (a). Statistical analysis was performed using one-way ANOVA followed by Tukey's multiple 
comparisons test. Results are presented as mean ± S.E.M. *, P < 0.05. **, P < 0.01, ***, P < 
0.001. ****, P < 0.0001. n = 6-12 animals per group. (d, e) Immunoblot analyses of kidneys 
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from the same groups as in (a) using antibodies for phospho-extracellular signal-regulated 
kinase (ERK) 1/2, total ERK1/2, and GAPDH as the loading control. Statistical analysis was 
performed using one-way ANOVA followed by Tukey's multiple comparisons test. Results are 
presented as mean ± S.E.M. *, P < 0.05. n = 4 animals per group. 
 
4.3.6 RIPK3 deficiency reduces collagen deposition in mice with FA nephropathy. 
To assess collagen deposition within the kidney cortex, we undertook picrosirius red staining 
(PSR) and immunohistochemistry to measure type I collagen protein expression. As shown in 
Fig. 4.6 a and b, FA nephropathy stimulated significant collagen deposition within the kidney 
cortex, which was decreased in RIPK3 deficient mice (all P<0.05). Collagen I was non-
significantly increased in the mice with FA nephropathy (P=0.0609, Fig. 4.6 a, c), which was 
decreased in RIPK3-/- mice (P<0.0001, Fig. 4.6 a, c). Thus, RIPK3 deletion reduced the increase 
in collagen accumulation observed in FA-induced nephropathy. 
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Figure 4.6 Increased collagen deposition in mice with folic acid nephropathy. (a) 
Representative images of picrosirius red staining (PSR) and collagen I stained kidney sections 
in mice (wild-type vs RIPK3-/-) with/without folic acid nephropathy. Scale bar: 200 μm. 
Magnification: 10× (left column); 40× (right column). (b) Quantitation of PSR staining in the 
same groups as in (a). (c) Quantitation of Collagen I immunohistochemical staining in the 
same groups as in (a). Statistical analysis was performed using one-way ANOVA followed by 
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Tukey's multiple comparisons test. Results are presented as mean ± S.E.M. *, P < 0.05. ***, 
P < 0.001. ****, P < 0.0001. n = 6-12 animals per group. 
 
4.3.7 Dabrafenib reduces TLR2/4 activation in mice with FA nephropathy. 
Given genetic deletion of RIPK3 does not reflect pharmacological inhibition of RIPK3 we 
assessed TLR2/4 signalling in mice with FA nephropathy in the presence or absence of 
dabrafenib. Dabrafenib showed a trend to downregulate the FA-induced elevation of RIPK3 
mRNA expression (P=0.0758, Fig. 4.7 a), although paradoxically, decreased phosphorylation 
of MLKL protein was observed (P<0.05, Fig. 4.7 f, g). Taken together with the lack of inhibition 
of MLKL observed in the RIPK3 knockout mice this suggests that MLKL expression may be 
regulated independent of RIPK3. Decreased TLR2 and TLR4 gene expression, as well as 
inhibition of downstream phosphorylated p65 and cytokines IL-1β and TNFα (Fig. 4.7 b, c, d, 
e, f, h), were also observed with dabrafenib treatment. These results indicate that dabrafenib 
suppresses the FA-induced TLR2/4 pathway activation and downstream inflammatory 
responses. 
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Figure 4.7 Reduced RIPK3 mediated TLR2/4 signalling in mice with folic acid-induced 
nephropathy treated with dabrafenib. (a-e) mRNA expression of RIPK3, TLR4, TLR2, IL-1β, 
TNFα were measured with q-PCR in mice (with or without treatment) with/without folic acid 
nephropathy. GAPDH was used as reference gene. Statistical analysis of genes was 
performed using one-way ANOVA followed by Tukey's multiple comparisons test. Results 
are presented as mean ± S.E.M. *, P < 0.05. **, P < 0.01. ***, P < 0.001. n = 6-12 animals per 
group.  (f-h) Immunoblot analyses of kidneys from the same groups as in (a) using antibodies 
for phospho-MLKL, total MLKL, phospho-p65, total p65 and GAPDH as the loading control. 
Statistical analysis was performed using one-way ANOVA followed by Tukey's multiple 
comparisons test. Results are presented as mean ± S.E.M. *, P < 0.05. **, P < 0.01. ***, P < 
0.001. n = 5 animals per group. 
 
4.3.8 Dabrafenib downregulates necroptotic NLRP3 inflammasome activation in mice with 
FA nephropathy. 
To understand if RIPK3 inhibition with dabrafenib blocks necroptotic NLRP3 inflammasome 
activation, inflammasome components were measured by RT-PCR. Similar to the results 
observed in RIPK3 deficient animals, dabrafenib reduced NLRP3 inflammasome formation in 
FA-induced nephropathy by downregulating NLRP3 and ASC mRNA expression (Fig. 4.8 a, b). 
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Figure 4.8 Reduced RIPK3 mediated NLRP3 inflammasome activation in mice with folic 
acid-induced nephropathy treated with dabrafenib. (a, b) mRNA expression of NLRP3, ASC 
were measured with q-PCR in mice (with or without treatment) with/without folic acid 
nephropathy. GAPDH was used as reference gene. Statistical analysis of genes was 
performed using one-way ANOVA followed by Tukey's multiple comparisons test. Results 
are presented as mean ± S.E.M. *, P < 0.05. ***, P < 0.001. n = 6-12 animals per group.  
 
4.3.9 Dabrafenib reduces inflammatory responses and histological evidence of renal injury 
in mice with FA nephropathy. 
To further study if dabrafenib protects the kidney against FA-induced nephropathy, we 
measured inflammatory responses and objective markers of renal injury. Consistently, MCP-
1 and F4/80 mRNA expression were downregulated by dabrafenib (P<0.05 for all, Fig. 4.9 a, 
b). Furthermore, dabrafenib significantly reduced FA-induced histological markers of injury as 
described above in the kidney cortex (P<0.0001, Fig. 4.9 c, d).  
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Figure 4.9 Reduced inflammatory response and kidney injury in mice with folic acid-
induced nephropathy treated with dabrafenib. (a, b) mRNA expression of MCP-1 and F4/80 
were measured with q-PCR in mice (with or without treatment) with/without folic acid 
nephropathy. GAPDH was used as reference gene. (c) Representative images of PAS-stained 
kidney sections from the same groups as in (a). Magnification: 1× (left column); 20× (right 
column). (d) Quantitation of renal cortical injury in the same groups as in (a). Statistical 
analysis was performed using one-way ANOVA followed by Tukey's multiple comparisons 
test. Results are presented as mean ± S.E.M. *, P < 0.05. **, P < 0.01. ***, P < 0.001. ****, P 
< 0.0001. n = 6-12 animals per group. 
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4.3.10 Dabrafenib alleviates myofibroblast activation in mice with FA nephropathy. 
Having demonstrated FA nephropathy is associated with elevated TGF-β1 signalling and 
myofibroblast activation, we sought to determine whether dabrafenib treatment limited 
renal injury by attenuation of the activation of these pathways in FA nephropathy. RT-PCR 
and immunohistochemistry indicated that dabrafenib treatment decreased TGF-β1 mRNA 
expression and p-ERK protein level (Fig. 4.10 a, d, e) without changing p-Smad2/3 (Fig. 4.10 b, 
c). Furthermore, dabrafenib significantly lowered α-SMA mRNA and protein expression, 
suggesting that dabrafenib effectively inhibits myofibroblast activation within the kidney 
cortex in FA nephropathy (P<0.05 for all, Fig. 4.10 f-h) but the lack of change in p-Smad2/3 
expression suggests this occurs independently of TGF-β1 signalling.   
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Figure 4.10 Reduced TGF-β1 signalling and myofibroblast activation in mice with folic acid-
induced nephropathy treated with dabrafenib. (a, f) mRNA expression of TGF-β1 and α-SMA 
were measured with q-PCR in mice (with or without treatment) with/without folic acid 
nephropathy. GAPDH was used as the reference gene. (b, g) Representative images of p-
Smad2/3 and α-SMA stained kidney sections from the same groups as in (a). Scale bar: 200 
μm. Magnification: 10× (left column); 40× (right column). (c, h) Quantitation of p-Smad2/3 
and α-SMA immunohistochemical staining in the same groups as in (a). Statistical analysis was 
performed using one-way ANOVA followed by Tukey's multiple comparisons test. Results are 
presented as mean ± S.E.M. *, P < 0.05. ***, P < 0.001. ****, P < 0.0001. n = 5-12 animals per 
group. (d, e) Immunoblot analyses of kidneys from the same groups as in (a) using antibodies 
for phospho-ERK1/2, total ERK1/2, and GAPDH as loading control. Statistical analysis was 
performed using one-way ANOVA followed by Tukey's multiple comparisons test. Results are 
presented as mean ± S.E.M. ***, P < 0.001. n = 5 animals per group. 
 
4.3.11 Dabrafenib decreases collagen deposition in mice with FA nephropathy. 
To examine total collagen deposition and specifically collagen I expression, kidney tissues 
were analyzed by picrosirius red staining and immunohistochemistry. Picrosirius red staining 
demonstrated increased collagen deposition in the kidneys of FA-induced nephropathy 
compared to control mice and significantly reduced collagen deposition in kidneys of mice 
treated with dabrafenib (Fig 4.11 a and b, P<0.01). Immunohistochemical analyses 
demonstrated increased collagen I in the kidney cortex of FA-induced nephropathy compared 
to control mice, which was reversed by dabrafenib treatment (Fig 4.11 a and c, P<0.01). This 
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data confirms that dabrafenib suppresses collagen deposition and specifically collagen I 
expression in FA nephropathy.  
 
Figure 4.11 Reduced collagen deposition in mice with folic acid-induced nephropathy 
treated with dabrafenib. (a) Representative images of PSR and collagen I stained kidney 
sections in mice (with or without treatment) with/without folic acid nephropathy. Scale bar: 
200 μm. Magnification: 10× (left column); 40× (right column). (b) Quantitation of PSR 
staining in the same groups as in (a). (c) Quantitation of Collagen I immunohistochemical 
staining in the same groups as in (a). Statistical analysis was performed using one-way 
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ANOVA followed by Tukey's multiple comparisons test. Results are presented as mean ± 
S.E.M. *, P < 0.05. **, P < 0.01. ****, P < 0.0001. n = 6-8 animals per group. 
 
4.4 Discussion 
In the present study, we defined the role of RIPK3 in renal fibrogenesis using a mouse model 
of FA-induced nephropathy. Our results demonstrate that RIPK3 is activated in FA-induced 
renal fibrosis. The fibrotic response was mitigated in the RIPK3-/- mice and in the wild-type 
mice treated with dabrafenib. Differential effects were observed on downstream TGF-β1 and 
MAPK activation in the 2 strategies used to limit RIPK3 activation. However, a reduction in 
TLR2 and 4 and NLRP3 activation was seen in both models concurrent with renoprotection, 
suggesting it is this pathway dominantly contributes to renal fibrosis.  
 
It is known the FA is directly toxic to renal tubular cells which is the primary mechanism of 
injury in this model with subsequent development of renal fibrosis. Previous reports have 
shown TLR2/4 activation induces tubular epithelial cell injury, resulting in upregulation of 
NFκB activation and consequent inflammatory and fibrogenic responses [349]. Our studies 
demonstrate that FA-induced nephropathy increases TNFα, which is known to be a key 
upstream regulator of RIPK3 [25], which in turn, acts upstream of the TLR2/4 pathway in 
tubular cells. We also report here that blocking of RIPK3 is associated with lower macrophage 
infiltration, inflammatory and fibrotic responses.  
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In support of our current findings, TLR2 and TLR4 have been previously demonstrated to be 
involved in renal inflammatory responses, leukocyte infiltration and fibrogenesis in various 
kidney diseases, such as ischemia/reperfusion injury, obstructive uropathy, tubulointerstitial 
nephritis and diabetic kidney disease [225, 234, 333, 350]. We have previously shown that 
blocking either TLR2 or 4 protects the kidney against tubular injury in diabetic kidney disease 
[258, 351]. Moreover, activation of TLR2/4 triggers NFκB nuclear translocation and 
transcription of proinflammatory cytokines, such as TNF α, IL-1 β [234, 352], which may 
amplify the necroptotic response. Our data have indicated that dabrafenib treatment only 
partially reduces RIPK3 mRNA expression, which is likely to be due to the differential inhibition 
of RIPK3 with the pharmacological inhibitor vs the knockout model. However, despite the 
modest reduction in RIPK3 TNF α was significantly reduced, which is likely to limit the 
amplification response.  
 
Previous studies have already postulated the deleterious role of NLRP3 inflammasome 
activation in the progression of renal inflammation and fibrosis [201]. NLRP3 deletion induces 
an increased repair response in tubular epithelial cells [353] and protects tubular cells from 
Angiotensin II-triggered cell injury [354]. Our study has revealed that blockade of RIPK3 in FA-
induced nephropathy decreases the expression of NLRP3 inflammasome components NLRP3 
and ASC, suggesting that RIPK3 may also promote tubular injury via activation of the 
inflammasome. 
 
It is well recognised that TGF-β1 regulates the activation of myofibroblasts and renal fibrotic 
responses at least partially through activation of TLR pathways [355]. mRNA levels of TGF-β1 
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are reduced in the kidneys of TLR4-/- mice [258]. TLR4 induces tubular cells and 
myofibroblasts to secrete extracellular matrix independent of the TGF-β/Smad pathway [222]. 
In addition, a novel and direct role of NLRP3 in promoting TGF-β1 mediated EMT in renal 
tubular epithelial cells has been confirmed [193]. TGF-β1 initiates canonical (Smad pathway) 
and non-canonical (non-Smad-based, p38, c-Jun N-terminal kinase (JNK) and MAPK) signalling 
pathways to exert multiple biological effects [355]. Our data elucidate that deletion of RIPK3 
reduces TGF-β1 mRNA expression and its myofibroblast activation, collagen accumulation as 
well as TGF-β1/Smad2/3 and ERK signalling pathways. However, renoprotection was 
observed in the dabrafenib treated FA-exposed mice with no significant change in the 
Smad2/3 or ERK signalling pathways. Hence, although we conclude that the benefits of RIPK3 
inhibition on TGF-β1 converge on the suppression of the TLR4 and inflammasome pathways 
it is possible that a reduction in TGF-β reduces a proinflammatory stimulus independent of 
the Smad pathway. 
 
It has been recently being independently reported that RIPK3 is implicated in renal 
fibrogenesis in two alternative models of renal fibrosis ie the unilateral ureteral obstruction 
(UUO) and adenine-induced models of CKD [22]. These studies confirmed our findings that 
inhibition of RIPK3 conferred renoprotection independent of downstream MLKL. Indeed, they 
found that RIPK3 induced fibrogenesis through the protein kinase B (PKB, also known as AKT) 
-dependent activation of ATP citrate lyase (ACL). Inhibition of RIPK3 suppressed TGF-β1 
phosphorylation of AKT and ACL in fibroblasts. With a reduction in extracellular matrix 
production and myofibroblast differentiation. However, RIPK3 did not alter the TGF-β1 mRNA 
expression at 7 days in the UUO mice [22] when renal fibrogenesis is likely to have been 
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instigated in the model. Hence it is likely that RIPK3 can upregulate multiple pathways 
involved in renal fibrogenesis, which may differ between cell types and depend on the 
strength of the fibrogenic stimuli. In our study, limitation of fibrogenesis in the FA model was 
driven by inhibition of the TLR2/4 and inflammasome pathways. 
 
These results suggest that the downstream activation of TLR2/4 signalling and NLRP3 
activation is an unrecognised mechanism in perpetuating tubular injury and the development 
of renal fibrosis in FA-induced nephropathy. Genetic deletion or pharmacological blockade of 
RIPK3 with dabrafenib attenuates kidney injury and renal interstitial collagen deposition via 
inhibition of the TLR2/4 pathway and NLRP3 activation in the mouse model of FA nephropathy. 
Therefore, targeting RIPK3 may be a therapeutic approach for the prevention of progressive 
kidney disease. Dabrafenib is currently available for human use and here we have shown that 
it can be repurposed for use in patients with renal fibrosis and likely progressive kidney 
disease.  
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Chapter 5 RIPK3 blockade attenuates tubulointerstitial 
fibrosis in a mouse model of diabetic nephropathy 
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Abstract 
Receptor-interacting protein kinase-3 (RIPK3) is a multifunctional regulator of cell death and 
inflammation. RIPK3 controls cellular signalling through the toll-like receptor (TLR) pathway 
and the formation of the domain-like receptor family pyrin domain-containing 3 (NLRP3) 
inflammasome, which have been well recognised to mediate renal fibrogenesis. The role of 
RIPK3 in diabetic kidney disease (DKD) induced renal fibrosis has not been previously 
determined. To define the action of RIPK3 in the development of DKD, wild-type (WT), RIPK3 
-/-, endothelium-derived nitric oxide synthase (eNOS)-/- mice were induced to develop 
diabetes mellitus using multiple low doses of streptozotocin and maintained for 24 weeks. 
RIPK3 expression was upregulated and fibrotic responses were increased in the kidney cortex 
of mice with established diabetic nephropathy compared to control mice. Consistently, mRNA 
expression of inflammasome components, TLR4 and interleukin (IL)-1β as well as TGF-β1 and 
α smooth muscle actin (α-SMA) were increased in diabetic kidneys of WT mice compared to 
control mice. However, these markers were normalised or significantly reversed in kidneys of 
diabetic RIPK3 -/- mice. Renoprotection was also observed using the RIPK3 inhibitor 
dabrafenib in eNOS-/- diabetic mice as demonstrated by reduced collagen and fibronectin 
deposition and myofibroblast activation. These results suggest that RIPK3 is associated with 
the development of renal fibrosis in DKD due to downstream activation of the NLRP3 
inflammasome and TLR4 and TGF1 signalling. Inhibition of RIPK3 results in renoprotection. 
Thus, RIPK3 may be a potential target for therapeutic intervention in patients with diabetic 
kidney disease. 
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5.1 Introduction 
End-stage kidney disease (ESKD) is a major cause of morbidity and mortality in patients with 
diabetes mellitus. Renal fibrosis indicates progressive renal disease will ensue in most forms 
of chronic kidney disease (CKD). In recent years, the increasing prevalence of diabetes mellitus 
accounts for the majority of chronic kidney disease worldwide [356]. The mainstay of therapy 
for diabetic kidney disease (DKD) is currently limited to controlling blood glucose and blood 
pressure, generally with an agent that blocks the renin-angiotensin system [357]. To date, no 
specific therapy for preventing diabetic kidney disease is available. A successful continuum 
between innovative discovery science and rigorous translation of research findings is required 
to improve the outcomes of patients with diabetic kidney disease.  
 
The receptor-interacting protein kinase (RIPK)3, a crucial kinase mediating necroptosis, has 
been implicated as a potential regulator of multiple inflammatory pathways, including toll-
like receptor (TLR)4 [358] and domain-like receptor family pyrin domain-containing (NLRP) 3 
inflammasome [23], which have been well established to promote tubular epithelial cell injury 
and interstitial fibrosis in various models of kidney disease, including DKD [13, 206, 258, 336, 
350, 359]. These studies suggest that RIPK3 may be a potential target to ameliorate DKD. 
Limiting the activation of the NLRP3 inflammasome and TLR4 by inhibiting RIPK3 has 
theoretical benefits in limiting renal fibrosis, including downstream effects on TGF1 
expression and signalling. However, the function of RIPK3 in the development of DKD has not 
been elucidated.  
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Dabrafenib, known as a B-Raf inhibitor, suppresses the downstream Ras/Raf/extracellular-
signal-regulated kinase (ERK)/ mitogen-activated protein kinase (MAPK) pathway [328] and 
has been approved by the U.S. Food and Drug Administration for the treatment of non-small 
cell lung cancer and melanoma expressing BRAFV600E mutations [329]. It is well documented 
that Ras/Raf/ERK/MAPK pathways are involved in renal fibrosis [331], suggesting dabrafenib 
may have renoprotective effects. Dabrafenib has also been reported to inhibit RIPK3 in mouse 
models of ischemic brain injury [327] and liver injury in human hepatocytes [326]. Compared 
to the other widely-used RIPK3 inhibitor GSK'872 [22, 323], dabrafenib shows more 
therapeutic potential for renal fibrosis because it has broader kinase inhibition. Given it is 
already in use in humans, repurposing for use in DKD is likely to have a facilitated route to 
market. 
 
In this study, we examined the role of RIPK3 in DKD induced renal fibrosis using a 
streptozotocin (STZ)-induced diabetic mouse model. We found that RIPK3 deficiency 
attenuated diabetes-induced renal fibrosis, associated with reduced activation of the NLRP3 
inflammasome, TLR4 and TGF1 signalling. Dabrafenib treatment also attenuated diabetes-
induced renal interstitial extracellular matrix (ECM) deposition and myofibroblast activation. 
Our data support the tenet that RIPK3 may mediate diabetes-induced fibrosis through the 
NLRP3 inflammasome and TLR4 pathway. Hence strategies that include inhibition of RIPK3 
may limit the development of diabetic kidney disease. 
 
5.2 Methods 
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5.2.1 Human kidney biopsies 
Human kidney biopsy specimens were collected from patients with clinically confirmed 
diabetic nephropathy by the Department of Anatomical Pathology of the Royal North Shore 
Hospital. Control kidney tissues were obtained from removed kidneys of patients, generally 
due to peripheral tumour but without known kidney disease. This study was approved by the 
Human Research Ethics Committee of NSLHD and Kolling Institute of Medical Research (HREC 
reference LNR/17/HAWKE/497). 
 
5.2.2 Animal studies  
7-9-week-old male wild-type (WT), RIPK3-/-, endothelium-derived nitric oxide synthase 
(eNOS)-/- mice (all C57BL/6 background) weighing 20-25g were used for this study. Mice 
were assigned to receive either 55 mg/kg STZ (Sigma-Aldrich) diluted in 0.1 M citrate buffer, 
pH 4.5, or citrate buffer alone by intraperitoneal injection for five consecutive days as 
described previously [257]. STZ-treated animals with blood glucose >16 mmol/L were 
considered as diabetic. eNOS-/-  mice were used to study the effect of dabrafenib on the 
development of diabetic nephropathy. Alzet model 2006 osmotic pumps (0.15µl/hr of 
dabrafenib dissolved in vehicle dimethyl sulfoxide (DMSO) at a concentration of 16.7 mg/ml) 
were implanted in the subcutaneous tissues in the interscapular region of eNOS-/-  diabetic 
mice to deliver dabrafenib or DMSO. Mice were weighed, and the blood glucose was 
monitored weekly with an ACCU-CHEK glucometer (Roche Diagnostics). Insulin (Lantus 2U/ 
day) was given subcutaneously if the blood glucose of mice exceeded 28 mmol or mice had 
significant weight loss (10-15% body weight loss in mouse with blood glucose >16 mmol/L). 
Mice were sacrificed 24 weeks after the induction of diabetes (as shown in Fig 5.1).  All 
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animals were housed in the Kearns Animal Facility of the Kolling Institute of Medical 
Research, with a stable environment maintained at 22 ± 1°C with a 2/12h light-dark cycle. 
Experiments were done in accordance with the National Health and Medical Research 
Council of Australia’s Code for the Care and Use of Animals for Scientific Purposes and were 
approved by the Animal Research Ethics Committee of the Royal North Shore Hospital 
(NSLHD reference RESP/15/206). 
 
 
Figure 5.1 Timeline of DM model and dual strategies to assess the effect of limitation of 
RIPK3 on the development of diabetic kidney disease. Male mice at 7-9 weeks of age were 
induced to develop diabetes using a regimen of 5 doses of STZ as described above. After a 
week, eNOS-/- diabetic mice underwent surgery to implant the pump to deliver dabrafenib 
or vehicle. Mice were sacrificed 24 weeks after inducing diabetes. 
 
5.2.3 RNA isolation and RT-PCR analysis 
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Total RNA was extracted from mouse kidney cortex using the RNeasy plus mini kit (Qiagen) 
by QIAcube (Qiagen). cDNA was synthesized with a cDNA synthesis kit (Roche). Predesigned 
probes (PrimeTime® Assay Std Probe 5' 6-FAM™/ZEN™/3' IB®FQ, Integrated DNA 
Technologies), including RIPK3 (Assay ID: Mm.PT.58.12712973.gs), Collagen IV ((Assay ID: 
Mm.PT.58.31838522), Fibronectin (Assay ID: Mm.PT.58.8135568), TGF-β1 (Assay ID: 
Mm.PT.58.11254750), α-SMA (Assay ID: Mm.PT.58.16320644), MCP-1 (Assay ID: 
Mm.PT.58.42151692), F4/80 (Assay ID: Mm.PT.58.11087779), TLR4 (Assay ID: 
Mm.PT.58.41643680), NLRP3 (Assay ID: Mm.PT.58.13974318), ASC (Assay ID: 
Mm.PT.56a.42872867),  IL-1 β (Assay ID: Mm.PT.58.41616450), Tubulin (Assay ID: 
Mm.PT.58.13069923) were measured. Tubulin was used as endogenous reference gene.  
 
5.2.4 Histology and Immunohistochemistry 
Kidney tissues were fixed in 4% paraformaldehyde and embedded with paraffin. 4 μm 
kidney sections were cut and stained as follows: After deparaffinisation with xylene, slides 
were immersed in decreasing concentration of ethanol (100%, 100%, 95%, 70%) and rinsed 
in a container of running water. Citrate buffer at pH 6 was heated to 99 ℃ for epitope 
retrieval. Slides were placed in hot retrieval buffer for 20 minutes incubation followed by 20 
minutes cooling to room temperature. Slides were blocked for 15 minutes (protein block 
serum-free ready to use x0909, Dako). Immunohistochemical staining was processed in 
Thermo Scientific Sequenza system. Slide were incubated overnight at 4℃ with primary 
antibodies as follows: RIPK3 (Abcam: ab56164), type I collagen (Abcam, ab34710, 1:750), 
type III collagen (Abcam, ab7778, 1:500), type IV collagen (Abcam, ab6586, 1:1000), 
Fibronectin (Abcam, ab 45688, 1:750), a-SMA (Sigma-Aldrich, A2547, 1:10000), p-Smad2/3 
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(Santa Cruz Biotechnology, sc-11769R, 1:150). Slides were then washed with TBS-T (50mM 
Tris, 150mM NaCl, 0.05% Tween 20, pH 7.6), and incubated with associated secondary 
antibodies (EnVision+system-HRP labelled polymer anti-rabbit k4003, Dako) for 30 minutes 
at room temperature. After washing with TBS-T, kidney sections were covered with DAB 
(liquid DAB+substrate chromogen system k3468, Dako) for 10 minutes. All experiments 
included controls without primary antibody. Staining was scored by multiplying the 
percentage of positive signals by the intensity. Score of intensity was from 1 to 5. Positive 
signals in the renal cortex regions were identified and quantified using Image J software. 
 
5.2.5 Statistical analysis 
The results are presented as mean ± S.E.M. The differences between two groups were 
analysed by two-tailed t-tests, and comparison of multiple groups was analysed by one-way 
analysis of variance ANOVA followed by Tukey's multiple comparisons test. The survival 
curves were analysed by Log-rank (Mantel-Cox) test. A two-sided p-value < 0.05 was 
considered statistically significant.  
 
5.3 Results 
5.3.1 Upregulation of RIPK3 expression in the diabetic kidney 
To determine whether RIPK3 is upregulated in diabetic kidney, RIPK3 protein expression was 
measured in kidney biopsies collected from normal nephrectomy specimens (Fig. 5.2a: Ctrl) 
and patients with established diabetic nephropathy (Fig. 5.2a: DN) using 
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immunohistochemistry. RIPK3 protein was clearly upregulated in proximal tubules (black 
arrows) of diabetic kidneys compared to normal kidneys.  
 
RIPK3 protein expression was examined using immunohistochemistry in kidneys of mice with 
or without diabetic nephropathy. Consistent upregulation of RIPK3 protein (black arrows) was 
observed in the kidneys of diabetic mice compared to control kidneys (Fig. 5.2b). mRNA 
expression of RIPK3 was assessed using RT-PCR. As shown in Fig. 5.2c, RIPK3 mRNA expression 
was significantly increased in diabetic mice compared to non-diabetic controls (P< 0.01). Our 
data indicate that RIPK3 is upregulated within the kidney in the context of diabetic kidney 
disease.  
 
 
Figure 5.2 Increased receptor-interacting protein kinase (RIPK) 3 in diabetic kidney disease.  
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(a) Representative images of RIPK3 stained kidney biopsies collected from normal 
nephrectomy specimens and patients with established DKD. Magnification: 20×. (b) 
Representative images of RIPK3 stained kidney sections in mice (wild-type WT or RIPK3-/-) +/- 
diabetes mellitus. Magnification: 20×. (c) RIPK3 mRNA expression fold change was measured 
by RT-PCR in the same groups as in (b). Tubulin was used as reference gene. Statistical analysis 
was performed using two-tailed t-tests. Results are presented as mean ± S.E.M. **P < 0.01. n 
= 14 animals for control group, n = 6 animals for DN group. 
 
5.3.2 RIPK3 gene knockout reduced fibronectin and collagen IV deposition induced by 
diabetes 
To investigate whether RIPK3 deficiency alleviates renal fibrogenesis, we compared WT and 
RIPK3 -/- mice, each with or without diabetes. The expression of the extracellular matrix (ECM) 
proteins fibronectin and type IV collagen were measured in the kidney cortex of mice by RT-
PCR and immunohistochemical analysis. As shown in Fig. 5.3 a, elevated fibronectin mRNA 
expression was found in diabetic WT mice compared to non-diabetic controls (P< 0.05). 
However, fibronectin mRNA expression levels in diabetic RIPK3-/- mice were significantly 
lower than that in the diabetic WT mice (P<0.05, Fig. 5.3 a). Similarly, type IV collagen mRNA 
expression was up-regulated in kidneys from diabetic mice compared to non-diabetic WT 
control (P< 0.05, Fig. 5.3 b). RIPK3 gene knockout reversed diabetes-induced type IV collagen 
mRNA expression in the kidney cortex compared to diabetic WT mice (P< 0.05, Fig. 5.3 b). 
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Consistent with the RT-PCR results, immunohistochemical analysis revealed increased 
staining of fibronectin and type IV collagen protein in the diabetic mice (all P< 0.05, Fig. 5.3 c, 
d, e), and reduced accumulation of both fibrotic markers in the kidney cortex of RIPK3 
knockout mice with diabetes (all P< 0.05, Fig. 5.3 c, d, e). 
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Figure 5.3 Increased fibronectin and collagen IV deposition in kidneys of diabetic mice. 
(a, b) Fibronectin and collagen IV mRNA expression was measured by RT-PCR in mice (WT or 
RIPK3-/-) +/- diabetes mellitus. Tubulin was used as reference gene. (c) Representative images 
of fibronectin and collagen IV stained kidney sections are from the same groups as in (a). 
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Magnification: 20×. (d, e) Positive area percentage quantitation of fibronectin and collagen IV 
immunohistochemical stains are from the same groups as in (a). Statistical analysis was 
performed by one-way analysis of variance ANOVA followed by Tukey's multiple comparisons 
test. Results are presented as mean ± S.E.M. *P < 0.05, **P < 0.01, ****P < 0.0001. n = 6-14 
animals per group.  
 
5.3.3 RIPK3 gene knockout decreased transforming growth factor beta (TGF-β)1 
expression and myofibroblast activation 
To understand the association between RIPK3 and ECM deposition we examined renal TGF-
β1 mRNA expression levels in diabetic WT and RIPK3 -/- mice using RT-PCR. Induction of 
diabetes in WT mice led to significantly increased TGF-β1 mRNA expression (P< 0.001, Fig. 5.4 
a), while TGF-β1 gene expression was reduced in RIPK3 -/- mice (P< 0.01, Fig. 5.4 a).  α-smooth 
muscle actin (α-SMA) gene expression is commonly regarded as a specific marker of 
myofibroblast differentiation downstream of TGF-β1 activation. Hence α-SMA mRNA was 
examined using RT-PCR. The data showed that α-SMA mRNA expression levels in kidneys of 
WT mice with diabetes were upregulated compared to non-diabetic mice (P< 0.01, Fig. 5.4 b). 
However, its expression levels were normalized in kidneys of diabetic RIPK3 -/- mice (P< 0.05, 
Fig. 5.4 b). These data suggest that disruption of RIPK3 suppresses TGF-β1 expression and 
myofibroblast differentiation in kidneys. 
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Figure 5.4 Increased transforming growth factor beta (TGF-β) 1 mediated myofibroblast 
activation in kidneys of diabetic mice.  
(a, b) TGF-β1 and α-smooth muscle actin (α-SMA) mRNA expression were measured by RT-
PCR in mice (WT or RIPK3-/-) +/- diabetic nephropathy. Tubulin was used as the reference 
gene. Statistical analysis was performed by one-way analysis of variance ANOVA followed by 
Tukey's multiple comparisons test. Results are presented as mean ± S.E.M. **P < 0.01, ***P 
< 0.001. n = 6-14 animals per group. 
 
5.3.4 RIPK3 gene knockout reduced kidney inflammatory cell infiltration 
It is well known that inflammatory cell infiltration plays a crucial role in progressive diabetic 
kidney disease. Thus, we measured monocyte chemoattractant protein (MCP)-1 and the 
mRNA expression of the macrophage marker F4/80. As shown in Fig. 5.5 a, MCP-1 mRNA 
expression was up-regulated in kidneys of diabetic WT mice compared to non-diabetic 
controls. However, this upregulation was partially reversed in diabetic RIPK3 -/- mice (all P< 
0.05). Similarly, F4/80 mRNA expression was increased significantly in the kidney cortex of 
diabetic WT mice compared to non-diabetic controls, whereas F4/80 mRNA expression in 
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kidneys of diabetic RIPK3-/- mice was much lower compared to diabetic WT mice (all P< 0.05, 
Fig. 5.5 b). Collectively, these data indicate that loss of RIPK3 led to suppressed inflammatory 
cell infiltration in the diabetic kidney cortex.    
 
W
T
 C
tr
l
W
T
 D
N
R
IP
K
3
-/
-  
C
tr
l
R
IP
K
3
-/
-  
D
N
0
1
2
3
4
M
C
P
-1
 m
R
N
A
 e
x
p
r
e
s
s
io
n
 l
e
v
e
l
* * * *
W
T
 C
tr
l
W
T
 D
N
R
IP
K
3
-/
-  
C
tr
l
R
IP
K
3
-/
-  
D
N
0
2 0
4 0
6 0
8 0
1 0 0
F
4
/8
0
 m
R
N
A
 e
x
p
r
e
s
s
io
n
 l
e
v
e
l
* * * * * * *
a b
 
Figure 5.5 Increased inflammatory cells infiltration in the kidneys of diabetic mice.  
(a, b) Monocyte chemoattractant protein (MCP)-1 and F4/80 mRNA expression were 
measured by RT-PCR in mice (WT or RIPK3-/-) +/- diabetes mellitus. Tubulin was used as the 
reference gene. Statistical analysis was performed by one-way analysis of variance ANOVA 
followed by Tukey's multiple comparisons test. Results are presented as mean ± S.E.M. *P < 
0.05, ***P < 0.001, ****P < 0.0001. n = 6-14 animals per group. 
 
5.3.5 RIPK3 gene knockout reduced TLR4 signalling activation 
To understand the role of RIPK3 in renal fibrosis and to identify the mechanism whereby RIPK3 
participates in TLR4 signalling, mRNA expression of TLR4 and its downstream interleukin (IL)-
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1β were measured using RT-PCR. As shown in Fig. 5.6 a, the expression of TLR4 was 
significantly up-regulated in diabetic WT mice compared to non-diabetic controls, while RIPK3 
gene knockout alleviated this up-regulation. mRNA expression of TLR2 only showed a trend 
of inhibition by the blockade of RIPK3 (data not shown). IL-1β mRNA was elevated in kidneys 
of diabetic WT mice and gene ablation of RIPK3 reversed this effect (all P< 0.05, Fig. 5.6 b). 
These data suggest that RIPK3 regulates activation of TLR4 signalling. 
 
Figure 5.6 Increased toll-like receptor (TLR) 4 signalling in kidneys of diabetic mice.  
(a, b) TLR4 and interleukin (IL)-1 β mRNA expression were measured by RT-PCR in mice (WT 
or RIPK3-/-) +/- diabetes mellitus. Tubulin was used as the reference gene. Statistical analysis 
was performed by one-way analysis of variance ANOVA followed by Tukey's multiple 
comparisons test. Results are presented as mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001. 
n = 6-14 animals per group. 
 
5.3.6 RIPK3 gene knockout reduced NLRP3 inflammasome formation 
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It is well documented that IL-1β serves as the active downstream cytokine of NLRP3 
inflammasome. To examine if RIPK3 regulates NLRP3 activation in the kidneys of diabetic mice, 
mRNA expression of the NLRP3 inflammasome components NLRP3 and the adapter protein 
apoptosis-related speck-like protein (ASC) were examined using RT-PCR. As shown in Fig. 5.7 
a, mRNA expression of NLRP3 was upregulated in kidneys of diabetic WT mice compared to 
non-diabetic controls (P< 0.001), and RIPK3 gene knockout completely reversed this effect 
(Fig. 5.7 a, P< 0.01). Consistently, ASC mRNA expression was significantly elevated in the 
kidney of diabetic WT mice compared to non-diabetic controls, whereas RIPK3 gene knockout 
also normalised ASC mRNA expression in diabetic kidneys (all P< 0.05, Fig. 5.7 b). Together, 
these data indicate that loss of RIPK3 reduces NLRP3 formation and activation within the 
diabetic kidney cortex. 
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Figure 5.7 Increased pyrin domain-containing protein (NLRP) 3 formation in kidneys of 
diabetic mice.  
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(a, b) NLRP3 and adapter protein apoptosis-associated speck-like protein (ASC) mRNA 
expressions were measured by RT-PCR in mice (WT or RIPK3-/-) +/- diabetes mellitus. Tubulin 
was used as reference gene. Statistical analysis was performed by one-way analysis of 
variance ANOVA followed by Tukey's multiple comparisons test. Results are presented as 
mean ± S.E.M. **P < 0.01, ***P < 0.001. n = 6-14 animals per group. 
 
5.3.7 Dabrafenib treatment increases survival rate in mice with established diabetic 
nephropathy. 
To study whether the RIPK3 inhibitor dabrafenib suppresses the progression of diabetic 
nephropathy and associated mortality, survival rates of mice after induction of diabetes were 
assessed over a period of 24 weeks. As shown in Fig.5.8, all control mice survived throughout 
the experimental period. Diabetic mice, without dabrafenib treatment, had a significantly 
decreased survival compared with control group (P=0.0015), reflecting a survival rate of 84.6% 
at day 10, decreasing to 76.9% at day 14. Further attrition occurred at the 134th, 135th day, 
166th day and 167th day) resulting in a 46.2% survival at the time of culling. However, 
dabrafenib treatment conferred an increased survival rate at each time point compared to 
untreated mice reflected in a survival rate of 75% after 24 weeks of diabetes. This data 
demonstrates that dabrafenib confers a survival benefit in the animals with diabetic kidney 
disease. 
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Figure 5.8 Decreased survival rate in diabetic mice. Survival rate eNOS-/- mice (with or 
without treatment) +/- diabetic nephropathy. The survival of eNOS-/- diabetic mice was 
monitored and compared to control mice (n = 14 for control group, n=13 for eNOS-/- diabetic 
group without treatment, n=12 for dabrafenib treated eNOS-/- diabetic group). After 24 
weeks, number of surviving mice in eNOS-/- diabetic group without treatment was 6, while 
dabrafenib treated eNOS-/- diabetic group had 9 mice. 
 
5.3.8 Dabrafenib treatment reduces ECM deposition in mice with established diabetic 
nephropathy 
To determine if dabrafenib alleviates diabetes-induced renal fibrosis, we performed 
immunohistochemistry to measure ECM deposition in the kidney. As shown in Fig.5.9 a and 
b, diabetic mice had significantly higher renal cortical collagen I expression, whereas this 
increase was reversed by dabrafenib treatment (P<0.0001). Similarly, diabetes-induced an up-
regulation of renal cortical collagen III, which was largely abrogated in dabrafenib treated 
mice (P<0.0001, Fig. 5.9 a, c). A similar upregulation was found in collagen IV expression that 
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was abrogated by dabrafenib (P<0.01, Fig.5.9 a, d). Furthermore, dabrafenib decreased 
diabetes-induced fibronectin protein expression (P<0.0001, Fig. 5.9 a, e). Thus, diabetes-
induced ECM deposition in the kidney was attenuated by dabrafenib treatment. 
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Figure 5.9 Increased extracellular matrix (ECM) deposition in kidneys of diabetic mice.  
(a) Representative immunohistochemical staining images of collagen I, collagen III, collagen 
IV and fibronectin in the renal cortex from eNOS-/- mice (with or without treatment) +/- 
diabetic nephropathy. Magnification: 20×. (b-e) The quantitation of collagen I, collagen III, 
collagen IV and fibronectin expression in mice kidneys. Statistical analysis was performed with 
ANOVA followed by Tukey's multiple comparisons test. Results are presented as mean ± S.E.M. 
*, P < 0.05. ***, P < 0.001. ****, P < 0.0001. n = 6-12 animals per group. 
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5.3.9 Dabrafenib treatment decreased myofibroblast activation and inflammatory 
response 
Given having demonstrated the upregulation of ECM and inflammasome markers in diabetic 
animal, we investigated whether dabrafenib reduced these markers predictive of CKD in 
diabetic mice. As shown in Fig 5.10 a and b, dabrafenib didn’t change the TGF-β expression 
but show a trend to reducing α-SMA (P=0.0643). Dabrafenib also suppressed the 
inflammatory response with a reduced MCP-1 (Fig. 5.10 c, P<0.05) and less F4/80 expression 
(Fig. 5.10 d, P<0.05). Although no statistical difference was found in expression of 
inflammasome components, dabrafenib displayed a trend to inhibit the NLRP3 inflammasome 
(Fig. 5.10 e, f). 
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Figure 5.10 Dabrafenib reduced the inflammatory response and trended to a reduction in 
mRNA expression of TGF-β1 and the inflammasome in kidneys of diabetic mice.  
(a-f) mRNA expressions of TGF-β, α-SMA, MCP-1. F4/80, NLRP3 and ASC were measured by 
RT-PCR in the renal cortex from eNOS-/- diabetic mice (with or without treatment). Statistical 
analysis was performed using two-tailed t-tests. Results are presented as mean ± S.E.M. *, P 
< 0.05. n = 6-12 animals per group. 
 
5.3.10 Dabrafenib treatment decreased myofibroblast activation in mice with established 
diabetic nephropathy 
Given no significant difference was observed in TGF1 mRNA but trends were observed to a 
reduction in α-SMA mRNA expression, we measured the α-SMA protein expression within the 
kidney cortex to investigate if dabrafenib reduces myofibroblast activation. As shown in 
Fig.5.11 a and b, diabetic mice showed significantly elevated α-SMA protein expression, 
whereas this effect was significantly reduced in mice exposed to dabrafenib (P<0.0001). 
 
To assess whether dabrafenib RIPK3 reduced TGF-β downstream Smad signalling 
independent of mRNA expression, we measured the p-Smad2/3 within the kidney cortex. As 
shown in Fig. 5.11 a and c, diabetes stimulated a significant up-regulation of p-Smad2/3 within 
the kidney cortex, which was decreased in dabrafenib treated mice similarly exposed to STZ 
(P<0.05). These data suggest that dabrafenib results in suppressed myofibroblast activation 
within the kidney cortex through inhibition of the Smad2/3 pathway, independent of a change 
in TGF-β mRNA expression, in the context of a diabetic nephropathy model. 
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Figure 5.11 Increased ECM deposition and pSmad2/3 expression in kidneys of diabetic mice.  
(a) Representative immunohistochemical staining images of α-SMA and p-Smad2/3 in the 
renal cortex from eNOS-/- mice (with or without treatment) +/- diabetic nephropathy. 
Magnification: 20×.  (b-c) The quantitation of α-SMA and p-Smad2/3 expression in mice 
kidneys. Statistical analysis was performed with ANOVA followed by Tukey's multiple 
comparisons test. Results are presented as mean ± S.E.M. *, P < 0.05. ***, P < 0.001. ****, P 
< 0.0001. n = 6-10 animals per group. 
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5.4 Discussion 
This study was undertaken to define the role of RIPK3 in regulating tubulointerstitial fibrosis 
in diabetic nephropathy. Significant up-regulation of RIPK3 was evident in the kidney cortex 
of animals and humans with diabetic kidney disease. RIPK3 deficiency downregulated TLR4 
signalling, NLRP3 inflammasome activation, and TGF-β1 expression and signalling, associated 
with a less inflammatory cell infiltration, myofibroblast activation and less ECM deposition. 
The RIPK3 inhibitor dabrafenib also replicates these renoprotective effects. 
 
Evolving data suggest that TLR4 signalling and the associated downstream cytokine IL-1β 
drives renal inflammation and fibrosis [206, 360-362]. Our group has previously shown that 
blocking TLR4 protects the kidney against tubular injury in in vivo and in vitro models of 
diabetic kidney disease [258, 349]. The NLRP3 inflammasome, the alternate source of IL-1β, 
also contributes to the progression of renal fibrosis [201]. It has been reported that NLRP3 
deletion protects against renal fibrosis and attenuates inflammation in diabetic mice [363] 
and mice with 5/6 nephrectomy [364]. In the present study, we found genetic deletion of 
RIPK3 reduced TLR4 signalling as well as NLRP3 inflammasome activation, associated with 
reduced ECM deposition and inflammatory cell filtration. Thus, we conclude the benefit of 
RIPK3 inhibition on inflammatory response may arise from inhibition of TLR4 and NLRP3 
activation, in addition to reduced expression and/or downstream signalling of TGF1. 
 
In our study, TGF-β1 was reduced by RIPK3 deficiency. Although no change in expression of 
TGF1 was observed in diabetic animals treated with dabrafenib, decreased phosphorylation 
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of p-Smad2/3was observed. A recent study also reported that TGF-β1 expression was not 
altered by RIPK3 deficiency in a 7-days unilateral ureteral obstruction (UUO) mouse model 
which is well recognised as a fibrogenic model. In this model, RIPK3 contributes to fibrosis via 
regulating proliferation of fibroblasts [22]. Hence RIPK3 may contribute to fibrosis through 
multiple pathways, depending on the cell type and the context of the fibrotic stimuli. However, 
the downregulation of TGF-β1 expression and/or downstream signalling by RIPK3 inhibition 
may still contribute to the reduction in renal fibrosis.  
 
It is well documented that activation of TLR4 and the NLRP3 inflammasome triggers 
downstream profibrotic pathways [365], including stimulation of TGF1 expression and 
signalling [363, 366], which serves to amplify the fibrotic response [367, 368]. Hence it is 
possible that inhibition of RIPK3 may directly inhibit TGF-β responses, or indirectly as a 
consequence of suppression of TLR4 and the NLRP3 inflammasome. 
 
There are several potential reasons why dabrafenib was not as potent in reducing 
inflammasome activation as was demonstrated in the RIPK3-/- animal. It is inevitable that the 
animals with genetic deletion of RIPK3 have greater inhibition of RIPK3 compared with a 
pharmacological inhibitor. Serum assays to determine the level of RIPK3 inhibition were not 
undertaken throughout the study. Furthermore, DMSO was used as the vehicle for dabrafenib 
delivery in our study. Despite the demonstrated toxicity of DMSO [369], it is recognised that 
DMSO administration may also lead to reduced transcription of inflammatory pathways 
[34,35]. Low concentrations of DMSO have been found to suppress CD4+ T cell activation, 
function, and metabolism [370]. A study has also demonstrated that DMSO attenuates NLRP3 
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inflammasome activation in macrophages and LPS-induced mice [371]. Hence, the magnitude 
of inflammation observed in the diabetic animals treated with DMSO may have been 
diminished. Additionally, the eNOS-/- mice may have different response towards the 
treatment of dabrafenib compared to wild-type mice. Moreover, the most severely affected 
mice from the eNOS-/- experiment had died which is very likely to cause bias to the conclusion. 
Therefore, the benefit of dabrafenib may have been attenuated.  
 
In summary, the results from these animal studies have demonstrated that RIPK3 is an 
important mediator of tubulointerstitial fibrosis in diabetic kidney disease. Furthermore, we 
have shown that blockade of RIPK3 exerts antifibrotic effects in the kidney that may arise due 
to a combination of inhibition of TLR4 signalling, NLRP3 inflammasome activation and TGF1 
expression and downstream signalling. 
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Chapter 6 Blockade of necroptosis attenuates fibrotic 
responses in human kidney proximal tubular cells exposed 
to TGF-β1 
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Abstract  
Necroptosis is increasingly recognised as a major regulator of inflammatory-related diseases, 
and in several conditions, necroptotic-blockade has been demonstrated to exert tissue 
protective effects. The inhibitor Nec-1s is a commonly used blocker of necroptosis. However, 
whether Nec-1s limits renal fibrosis is unclear. We utilised a human in vitro model, whereby 
human proximal tubular (HK2) cells were incubated with or without transforming growth 
factor beta (TGF-β) 1 (2ng/ml) for 48h in the presence or absence of the inhibitor Nec-1s (80 
µM). We found Nec-1s treatment reduced the amplification of mRNA expression of TGF-β1, 
as well as the extracellular matrix (ECM) proteins (collagen I, collagen III, collagen IV and 
fibronectin). Our results indicate that Nec-1s may limit renal fibrosis via inhibiting TGF-β1 
mediated ECM secretion in kidney proximal tubular cells. 
 
 
6.1 Introduction 
Renal fibrosis is common to all forms of progressive kidney disease. It is characterized by 
extracellular matrix (ECM) accumulation, myofibroblast activation and increased 
inflammation, causing renal dysfunction and ultimately end-stage kidney disease (ESKD) [372]. 
However, to date, specific therapies for preventing progression of renal fibrosis are lacking.  
 
Necroptosis is a type of regulated necrosis activated by ligands of death receptors and stimuli 
that induce the expression of death receptor ligands under apoptotic deficient conditions. It 
serves essential functions in both development and tissue homeostasis [373]. The classic 
necroptosis pathway includes three key interacting kinases, 
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 receptor-interacting serine/threonine-protein kinase (RIPK) 3, RIPK1 and mixed lineage 
kinase domain-like protein (MLKL). The necrosome formed by RIPK3 and RIPK1 is the trigger 
to activate the necroptosis executioner MLKL and then induce necroptosis [15]. Conversely, 
deletion or inhibition of RIPK3, RIPK1 or MLKL prevents cells from undergoing necroptosis [18-
20, 374-376]. Necrostatin-1/1s (Nec-1/Nec-1s), is a widely used inhibitor of necroptosis [16, 
17, 377, 378], effectively reducing necroptosis via inhibiting the kinase RIPK1 activity with an 
IC50 of 0.367 µM in the induced necroptosis L929sAhFas cell model [379].  
 
Recent studies have reported that inhibition of necroptosis with the inhibitor Nec-1 shows a 
protective effect against the interstitial fibrotic response in the kidney in both the unilateral 
ureteral obstruction (UUO) mouse model [16] and in rats subjected to subtotal nephrectomy 
(SNx) [17]. In the UUO model, Nec-1 treatment reduced TGF-β gene expression [16]. Given 
that UUO is a classic animal model of studying tubulointerstitial fibrosis, these results indicate 
the antifibrotic function of Nec-1 may relate to inhibition of TGF-β effects on tubular cells.  
 
It is well recognized that TGF-β1 is a principal mediator of renal fibrosis in all forms of kidney 
disease. There is now a large amount of literature to support that TGF-β1 is responsible for 
promoting tubulointerstitial fibrosis through tubular cell injury [380, 381]. The renal tubular 
epithelium is also considered as the effector of tubulointerstitial fibrosis, secreting 
profibrogenic cytokines and chemoattractants to enhance the inflammatory response [381]. 
Ultimately, tubular cells may also undergo epithelial to mesenchymal transition and acquire 
a myofibroblastic phenotype. Human proximal tubular cells (HK2 cell line) are widely used 
for studying renal fibrosis in cell culture [382]. Therefore, in this study, we studied the 
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antifibrotic potential of blockade of necroptosis and the mechanisms underpinning 
renoprotection in the HK2 cell line exposed to TGF-β1. Nec-1s, which is more potent in 
inhibiting necroptosis than is Nec-1 [383], was used as a necroptotic inhibitor in our study. 
Our results demonstrate that Nec-1s attenuates ECM secretion induced via downregulation 
of TGF-β1. 
 
6.2 Methods 
6.2.1 Cell culture 
HK2 cells were grown in keratinocyte serum-free medium (Invitrogen, CA). After reaching 
60% confluence, cells were exposed to TGF-β1 (2 ng/ml) (R&D) plus the vehicle dimethyl 
sulfoxide (DMSO) (final concentration in culture medium was less than 0.1%) or Nec-1s (80 
µM) (Biovision) in DMSO and incubated for 48 hours. Culture medium supernatant, cell 
lysates and total RNA were collected for further analyses. 
 
6.2.2 Cell viability assay 
For the cell proliferation assays, cells were seeded into each well of a 96-well plate (5 × 103 
per well). After 24 hours, cells attached to the plate and then were incubated with Nec-1s in 
vehicle DMSO (40, 60, 80, 100, 160, 320, 400 µM) for 24 hours. Cell proliferation was 
determined with a CellTiter 96® AQueous Non-Radioactive Cell Proliferation. This assay uses 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H tetrazolium 
(MTS) that changes to formazan in cells with mitochondrial activity (viable cells). Formazan 
was measured at 490 nm with a microplate reader. 
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6.2.3 RNA isolation and RT-PCR analysis 
Total RNA was extracted from cells using ISOLATE II RNA Mini Kit (Bioline). The cDNA was 
synthesized with a cDNA synthesis kit (Roche). Predesigned probes, including tubulin (Assay 
ID: Hs.PT.58.27209704), collagen IV (Assay ID: Hs.PT.58.15679435), fibronectin (Assay ID: 
Hs.PT.58.40005963), TGF-β1 (Assay ID: Hs.PT.58.39813975) were measured. Tubulin was 
used as the endogenous reference gene. 
 
6.2.4 Western blot analysis 
Proteins in the supernatant were separated on 4-12% gels (Invitrogen) and then transferred 
to PVDF membrane (PALL) for 2 hours at 4 ℃. Membranes were blocked with 5% BSA in 
TBS-T (20 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.6) for 1 hour and then incubated 
with primary antibodies (collagen I, Abcam, ab34710; collagen III, Abcam, ab7778; collagen 
IV, Abcam, ab6586; fibronectin, Abcam, ab45688) and relevant horseradish peroxidase-
conjugated secondary antibody (anti-Rabbit antibody, Cell Signalling). 
 
6.2.5 Statistical analysis 
The results are presented as mean ± S.E.M. All statistical analyses were performed with 
GraphPad software. Comparison of multiple groups was analysed by one-way analysis of 
variance ANOVA followed by Tukey's multiple comparisons test. A two-sided p-value < 0.05 
was considered statistically significant. 
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6.3 Results 
6.3.1 Inhibition of necroptosis decreased ECM secretion in HK2 cells exposed to TGF-β1. 
In the present study, we used the MTS to measure the toxicity of Nec-1s. As shown in Fig 
6.1a, Nec-1s inhibited cell proliferation in a concentration-dependent manner. However, 
even with a high concentration of 400 µM, the mean of the proliferation rate was 0.7729, 
suggesting a low toxicity of Nec-1s. 
 
 
Figure 6.1 Toxicity of Nec-1s.  
Proliferation rate was measured with MTS in HK2 cells exposed to the inhibitor Nec-1s at the 
above concentrations. Statistical analysis was performed by one-way analysis of variance 
ANOVA followed by Tukey's multiple comparisons test. Results are presented as mean ± S.E.M. 
****P < 0.0001 vs control. n = 6.  
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To explore the function of Nec-1s, fibronectin and type IV collagen gene expression were 
measured in HK2 cells exposed to TGF-β1 with or without the necroptosis inhibitor Nec-1s at 
a concentration of 80 µM using RT-PCR. TGF-β1 treatment stimulated fibronectin gene 
expression (P< 0.001, Fig.6.2a), as well as type IV collagen gene expression (P< 0.05, 
Fig.6.2b). Nec-1s at a concentration of 80 µM showed strong inhibition of both genes (Fig 
6.2 a, b, both P<0.05). Western blotting experiments also confirmed that TGF-β1 increased 
collagen I, III, IV and fibronectin protein expression (Fig. 6.2c, d, e, f, g, all P<0.05), while 
Nec-1s reversed this effect (6.2c, d, e, f, g, all P<0.05). These data suggest that Nec-1s 
treatment significantly reduces TGF-β1-induced ECM secretion in tubular cells. 
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Figure 6.2 Increased collagen IV and fibronectin secretion in HK2 cells exposed to TGF-β1.  
(a) Fibronectin mRNA expression fold change was measured by RT-PCR in HK2 cells exposed 
to TGF-β1 with or without the inhibitor Nec-1s. (b) Collagen IV mRNA expression fold change 
was measured by RT-PCR in the same group as in (a). Tubulin was used as the reference gene 
for RT-PCR. (c-g) Immunoblot analysed cells from the same groups as in (a) using antibodies 
for collagen I, collagen III, collagen IV, fibronectin. Statistical analysis was performed by one-
way analysis of variance ANOVA followed by Tukey's multiple comparisons test. Results are 
presented as mean ± S.E.M. *P < 0.05, ***P < 0.001. n = 4. 
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6.3.2 Inhibition of necroptosis downregulated TGF-β1 expression 
Having established that TGF-β1 treated HK2 cells secrete elevated levels ECM, we sought to 
determine whether these stimulated cells themselves exhibited increased TGF-β1 
expression. RT-PCR results demonstrated that TGF-β1 treatment significantly increased TGF-
β1 gene expression (P< 0.01, Fig.6.3a), thus amplifying the fibrotic response. We also 
observed that this upregulation was partially reversed by Nec-1s treatment (P< 0.05, 
Fig.6.3a), suggesting that Nec-1s treatment may limit tubulointerstitial fibrosis by reducing 
endogenous TGF-β1 mRNA expression. 
 
Figure 6.3 Increased TGF-β1 mRNA expression in HK2 cells exposed to TGF-β1.  
(a) TGF-β1 mRNA expression fold change was measured by RT-PCR in HK2 cells exposed to 
TGF-β1 with or without the inhibitor Nec-1s. Tubulin was used as the reference gene for RT-
PCR. Statistical analysis was performed by one-way analysis of variance ANOVA followed by 
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Tukey's multiple comparisons test. Results are presented as mean ± S.E.M. *P < 0.05, **P < 
0.01. n = 4. 
 
6.3.3 Inhibition of necroptosis showed a trend to downregulate phosphor-extracellular-
signal-regulated kinase (ERK) but not p38 expression 
To further study the mechanism, we measured the phosphorylation level of ERK and p38 
using western blot. HK2 cells showed higher phosphorylation levels of ERK in the presence 
of TGF-β1 (P< 0.05, Fig.6.4a, b). However, this effect showed a trend to be reduced by Nec-
1s treatment (P=0.0721, Fig. 6.4a, b), indicating that Nec-1s treatment may decrease the 
fibrotic response partially via regulating ERK activation. However, no trend was seen for 
Nec-1s to reduce the TGF-β1-induced phosphorylation of p38. (Fig. 6.4 a, c). 
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Figure 6.4 Increased ERK and p38 activation in HK2 cells exposed to TGF-β1. 
(a, b, c) Immunoblot analysis of HK2 cells exposed to TGF-β1 with or without the inhibitor 
Nec-1s. using antibodies for phosphor-ERK, total ERK, phosphor-p38, total p38. Statistical 
analysis was performed by one-way analysis of variance ANOVA followed by Tukey's multiple 
comparisons test.  Results are presented as mean ± S.E.M. *P < 0.05, n = 4. 
 
6.4 Discussion 
In the current study, we investigated whether inhibition of necroptosis blocks the fibrotic 
response in HK2 cells exposed to TGF-β1. Our results showed that exogenous TGF-β1 
amplified endogenous tubular cell TGF-β1 mRNA expression, which was accompanied by 
increasing ECM secretion and ERK activation. Moreover, the findings suggest that Nec-1s 
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inhibition of necroptosis leads to a reduction of ECM secretion and TGF-β1 expression. 
Taken together, these findings suggest that necroptosis may be involved in fibrogenesis via 
mediating downstream activation of TGF-β1 as well as auto amplification of the TGF-β1 
response. 
 
ECM deposition is the main histological feature of renal fibrosis. It is well established that 
TGF-β1 is one of the most potent cytokines regulating ECM synthesis, with tubular cells and 
myofibroblasts, which in turn, are often derived from tubular cells, being a significant source 
of TGF-β1. Downstream TGF-β1 signalling through stimulates the synthesis and 
overproduction of  various ECM proteins, including collagens and fibronectin, accounting for 
the interstitial fibrosis [384]. Of note, in this study, protein levels of Collagens -1, -3 and IV 
as well as fibronectin were increased by TGF-β1 and reversed by Nec-1s, which supports our 
hypothesis that blockade of necroptosis suppresses TGF-β1 induced ECM secretion in 
tubular cells. These results are also consistent with our previous findings in in vivo studies, 
that blockade of RIPK3 reduces TGF-β1 within the kidney cortex, indicating the benefit of 
RIPK3 inhibition may partially arise from abolishing necroptosis in tubular cells.  
 
TGF-β1 induces a fibrotic response by activating Smad mediated and non-Smad signalling 
cascades, such as Ras/Raf/ERK/ mitogen-activated protein kinase (MAPK) pathways, 
p38/MAPK pathways [9]. However, the activation of p38/MAPK in renal fibrosis occurs in 
conjunction with Smad2/3 [179, 181-184]. The present study also shows inhibition of 
necroptosis failed to regulate p38, and hence unlikely to also involve Smad 2/3. 
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In non-Smad signalling, only ERK contributes to the autoinduction of TGF-β1 [169]. It is also 
reported that activation of the ERK signalling Is required for TGF-β1-Induced epithelial-to-
mesenchymal transition (EMT) in NMuMG and MCT (mouse proximal tubule epithelial cells) 
[385]. Given that we obtained consistent suppression of myofibroblast activation and showed 
a trend to inhibition of ERK phosphorylation with inhibition of RIPK3 in in vivo studies, ERK 
activation may play a role in renal fibrosis. Similar to the effect of RIPK3 deficiency or 
dabrafenib, Nec-1s treatment only exhibited a partial suppression of the ERK pathway. Thus, 
we conclude ERK signalling is not a major pathway in necroptosis mediated TGF-β1 cascades. 
However, it remains possible the beneficial effect of dabrafenib may be partially driven by 
inhibition of ERK in conjunction with inhibition of RIPK3. 
 
Nec-1s, a widely used to block necroptosis as it abolishes the RIPK1/RIPK3 necrosome 
formation and ensuing necroptosis [312-314, 386]. Hence it is a useful pharmacological tool 
to study necroptosis but not necessarily to investigate the individual contribution of RIPK1 
or RIPK3 to the necroptotic response. Given that RIPK1 shows dual influences on necroptosis 
in other models of fibrosis [315], the role of RIPK1 in tissue and organ-specific models of 
renal fibrosis needs to be further explored. 
 
In summary, the present study demonstrated that ablation of necroptosis significantly 
suppressed TGF-β1 expression, as well as TGF-β1-induced ECM secretion in proximal tubular 
cells. Nec-1s showed a trend to be associated with suppression of ERK activation. However, 
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it is possible that other downstream signalling pathways of TGF-β1 may also be involved. 
This study provides a basis for further investigating the therapeutic potential of necroptosis 
inhibition in the prevention of renal interstitial fibrosis. 
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Chapter 7 Conclusions and future directions 
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7.1 Conclusions  
CKD represents an increasing component of the health burden and economic cost of non-
communicable disease in the developed and developing world [3, 4]. CKD is characterized 
functionally by a drop in glomerular filtration rate and development of albuminuria and 
histologically by ECM accumulation, myofibroblast activation and inflammatory responses, 
which collectively comprise the features of renal fibrosis.  Renal fibrosis is the pathological 
endpoint of all renal disease across the spectrum of causes of CKD and ESKD.  CKD due to 
multiple causes, but primarily due to repeated episodes of acute or toxic kidney injury or 
diabetic kidney disease affects a large number of the population worldwide. Hence it is 
appropriate to focus on treatment strategies that interrupt the development of fibrosis in 
addition to upstream factors that may be specific to certain diseases.  
 
Given that clinical strategies based on current findings for the prevention or management of 
renal fibrosis remain unsatisfactory [122, 235], and the rising importance of innate 
immunity in fibrotic response has been reported, we hypothesised RIPK3 as a novel target 
and utilised the toxin-induced FA model of acute toxic nephropathy followed by the 
development of CKD and a STZ induced diabetic model to test our hypothesis. An in vitro 
study was also done to explore the role of necroptosis in the fibrotic response. Our results 
are described in detail in each chapter and in summary form in Chapter 1.  
 
Collectively, the principal finding in the thesis is the identification of RIPK3 as a crucial 
regulator of renal fibrosis. I have identified RIPK3 mediated TLR4 signalling and NLRP3 
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inflammasome activation, key contributors to the development of renal fibrosis, in addition 
to known TGF1 dependent signalling pathways that may be downstream of activation of 
RIPK3 activation of TLR4 signalling and the NLRP3 inflammasome and dependent on the 
model of CKD. My data provide evidence of the powerful effect of RIPK3 on fibrogenesis and 
strongly suggests that dabrafenib should be considered for repurposing to target RIPK3 to 
limit the development of CKD. 
 
7.2 Future directions 
The results of this thesis showed blocking RIPK3 reduced IL-1β mRNA expression in both the 
FA and diabetic CKD models. IL-1β serves as the downstream cytokine of both NLRP3 
inflammasome and TLR2/4-NFκB cascades. However, the data generated from the FA model 
suggests NFκB is not primarily activated, suggesting IL-1β may mainly originate from 
inflammasome activation, thus confirming our conclusion NLRP3 activation is a major 
downstream mediator of RIPK3. Although not the focus of this thesis, targeting of IL1β has 
received very recent attention for the treatment of cardiovascular disease [387] and more 
recently interest to prevent the development and progression of CKD [388]. My data would 
support further targeted studies into using monoclonal blockers of  IL-1β to assess the effect 
on progressive kidney disease.  
 
As I discussed in Chapter 2, the NLRP3 inflammasome activation contributes to tubular 
injury and renal fibrosis. NLRP3 is the crucial component of inflammasome complex, 
deletion of which protected PTCs from NLRP3 inflammasome activation in Ang II-infused 
mice [354]. Similarly, NLRP3 deficiency attenuated tubulointerstitial fibrosis as 
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demonstrated by reduced ECM deposition and decreased cell apoptosis in a mouse UUO 
model [340]. In vitro studies further confirmed suppression of EMT as well as α-SMA in renal 
PTCs exposed to TGF-β [193]. An inflammasome-independent role of NLRP3 has been 
proposed, given that the effect of NLRP3 on α-SMA expression was shown to be 
independent of the inflammasome and associated IL-1β expression [193]. A similar result 
was observed in the mouse model of renal ischemia-reperfusion injury, where loss of NLRP3 
but not ASC protected tubular cells from necrosis and apoptosis. In our FA model, blocking 
RIPK3 showed a trend to reduce ASC, which was more convincingly demonstrated in the DN 
model. Compared to ASC, ablation of RIPK3 reduced NLRP3 expression significantly in both 
the FA and DN models, suggesting the benefit of blocking RIPK3 may arise from independent 
effects on both the inflammasome and on NLRP3. Thus, dissection of these individual 
components and their contribution to benefits derived from interruption or inhibition of the 
RIPK3 mediated pathway would be worthy of exploration in the future.  
 
Several recent studies have established the significant roles of TLR2 and 4 in the 
development of kidney injury and fibrosis. Although TLR2 and TLR4 are often observed to be 
contemporaneously increased in various models of renal disease, TLR2 induces pro-
inflammatory responses while TLR4 mediates both pro-inflammatory and pro-fibrotic 
pathways [206]. In my studies, both in vivo models upregulated TLR2 and TLR4 expression. 
In the FA model, lack of RIPK3 reduced expression of both receptors. However, only TLR4 
was downregulated by RIPK3 deficiency in the DN model. In considering these differences, 
the FA model is studied at 28-day i.e in the chronic phase after FA-induced tubular injury, at 
which stage persistent inflammatory stimulation is reduced. In contrast, hyperglycaemia is a 
persistent stimulus in the DN model. Hence our data may suggest a positive feedback loop 
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regulation between RIPK3 and TLR2 exists and differ dependent on the strength of the 
inflammatory stimuli. Experiments with graded inflammation and concomitant TLR2 
blockade are required to dissect the two pathways. 
 
We have demonstrated that TGF-β is regulated by RIPK3 in both the FA model and diabetic 
model of CKD. A reduction of TGF-β expression was also observed in Nec-1s treated PTCs. 
Thus, inhibition of both RIPK3 and necroptosis downregulate TGF-β expression +/- activity. 
Given the role of RIPK3 in necroptosis, these results support the basis of our hypothesis that 
targeting RIPK3 contributes to renal fibrosis via multiple mechanisms occurring in parallel. 
 
It is well recognized that downstream signalling of TGF-β includes Smad and non-Smad 
mediated signalling cascades such as the Ras/Raf/ERK/MAPK pathways. To further 
investigate the RIPK3-sensitive downstream mediators of TGF-β, we measured these 
downstream mediators in our studies. Smad2/3 was downregulated in RIPK3-/- mice with 
FAN as well as in diabetic mice treated with dabrafenib. Therefore, we conclude Smad2/3 
signalling is an important mechanism in mediating downstream effects of RIPK3 activation. 
The regulation of Smad2/3 signalling by RIPK3 may differ depending on the context of injury 
and needs validation in differing models of renal disease. Expression of pERK showed a 
consistent trend to reduction in both in vivo and in vitro studies. Although no significant 
changes were found, the function of this pathway in RIPK3/TGF-β mediated inhibition of 
fibrosis cannot be excluded given the trend to significance was high. Non-Smad pathways, 
such as the JNK, and Rho-like GTPase signalling pathways deserve further exploration in 
future studies. 
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Using a universal knock out animal model resulting in RIPK3 deficiency is a potential 
limitation of our study in defining mechanistic effects. Investigating mechanistic aspects 
underpinning any therapeutic potential is limited by this approach. A tubular-specific knock 
out model would be required to assess tubular specific effects of RIPK3 in the contribution 
of the tubular cell to renal fibrosis. Such a model could be the focus of future studies to 
develop specific therapies. Having said this, organ and cell-specific knockout and 
overexpression strategies have limited relevance to therapeutic interventions which are 
generally unable to be targeted to organs or tissues but have global effects.  
 
Dabrafenib was used as the RIPK3 inhibitor in our study and deliberately chosen to allow 
differentiation of the RIPK3 dependent pathways (as demonstrated in the RIPK3-/- animals) 
from other kinase-dependent pathways also inhibited by dabrafenib. As I discussed in 
Chapter 2, dabrafenib can inhibit Ras/Raf/ERK/MAPK activation [328], and hence is used in 
targeted therapy for melanoma and non-small cell lung cancer expressing B-Raf V600E 
mutations [329]. Hence it has broader therapeutic potential beyond its actions as a RIPK3 
inhibitor. As discussed in Chapter 2, Ras/Raf/ERK/MAPK serves as a downstream pathway of 
TGF-β and contributes to renal fibrosis. However, only a trend for ERK inhibition by 
dabrafenib was observed in our study.  These off-target effects of dabrafenib on 
Ras/Raf/ERK/MAPK may contribute to its renoprotection effects. A higher dose of 
dabrafenib is worthy of investigation in an animal model of renal fibrosis.  
 
The toxicity of dabrafenib has been fully investigated as required prior to approval for 
clinical use.  A single patient has been reported to develop nephrotic syndrome during 
treatment with dabrafenib in combination with another BRAF inhibitor trametinib [389]. 
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However, kidney function and glomerular ultrastructural changes fully recovered after drug 
withdrawal. In patients receiving dabrafenib therapy in the Food and Drug Administration 
Adverse Event Reporting System, quarterly legacy data file from the second quarter of 2013 
through second quarter of 2014, thirteen cases were reported as having acute kidney injury 
due to tubulointerstitial injury [390]. The reasons for acute kidney injury are unclear, but 
given the drug was administered in patients receiving concomitant therapies for malignancy 
there are likely to be multiple mechanisms predisposing to acute kidney injury. A study also 
indicated that the dabrafenib associated nephrotoxicity may be age-dependent [391]. 
Although very few reported have been published on nephrotoxicity of dabrafenib, dedicated 
clinical studies in patients with would be demanded before repurposing this drug for kidney 
disease. 
 
Compared to the enormous costs and money for the approval of a new drug, this drug may 
be easier to repurpose for use in patients with CKD with less time and cost. Clinical trials 
using dabrafenib to slow the development of CKD should be supported, with or without 
pharmaceutical support. 
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